Regulation of Wnt/β-Catenin Signaling in Cardiac Valve Development and Disease by Guo, Lilong
Medical University of South Carolina 
MEDICA 
MUSC Theses and Dissertations 
2020 
Regulation of Wnt/β-Catenin Signaling in Cardiac Valve 
Development and Disease 
Lilong Guo 
Medical University of South Carolina 
Follow this and additional works at: https://medica-musc.researchcommons.org/theses 
Recommended Citation 
Guo, Lilong, "Regulation of Wnt/β-Catenin Signaling in Cardiac Valve Development and Disease" (2020). 
MUSC Theses and Dissertations. 538. 
https://medica-musc.researchcommons.org/theses/538 
This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in 
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact 
medica@musc.edu. 









A dissertation submitted to the faculty of the Medical University of South 
Carolina in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in the College of Graduate Studies 








Chairman, Advisory Committee         
      Russell (Chip) Norris 
 
         
                       
Robin C. Muise-Helmericks 
 
    
                       
                                                                                     Jeffrey Jones 
 
 











        I would like to dedicate this work to my family: my lovely wife Ying, 
my cutest sons Molin and Moqi, my parents and in laws. Their support and 
patience and relentless understanding have been an enormous help in 
accomplishing this work. To my wife Ying for taking care of most of the 
housework and share the joy and pain that I have been going through, for 
accompany when I feel frustrated and encouragement when I feel pessimistic. 
To my mom and dad for always supporting my every decision and offering 
unconditional love to me and my family. To my parents in law for looking 
after our sons and supporting us both mentally and financially. Thanks also to 
the members of the #norrislab Diana, Tyler, Kate, Kathrine, Amanda, Kelsey, 
Janiece, Rebecca, Cortney, Natalie, Jorden. Without their daily support, 
collaboration and funny jokes this would not have been possible. Last but not 
least I would like to thank the friends that I have met here, Zequn, Fei, Hao 
and Peiheng, who are always there to offer help when I need a hand and 
always there to talk when I need a break. They are like my families and the 







        First of all, the accomplishment of this study is attributed to Dr. Russell 
(Chip) Norris, whose unconditional support and critical guidance during the 
five years have assisted in leading this project to the right direction. His 
philosophy in running the lab and doing science have helped build a positive 
image of a scientist that I want to become. Without his mentorship, nothing 
would have happened. Furthermore, assistance from my lab mates is playing 
a key role in finalization of this study. Their enthusiasm in science encourages 
me to push myself a little further to where I am right now. In addition, I would 
like to acknowledge my committee, Dr. Kourtidis, Dr. Jones and Dr. 
Lipschutz who is also my co-mentor, they sincerely provided me experiment 
tips and suggestions which have helped shape this work. Special thanks to Dr. 
Muise-Helmericks who pulled me out of swamp when I was enduring bumps 
during the first two years. Her encouragement and advises enlightened me and 
cheered me up helping me get through the darkness. Whiteout her intervention, 
I might have already dropped off the program and would have not completed 
this work. Also, I would like to acknowledge the members of the department 
of Regenerative Medicine and Cell Biology for always being there to help. 
Their industrial working attitude inspires me to become a better scientist. Last 
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LILONG GUO. Regulation of Wnt/β-Catenin Signaling in Cardiac Valve 
Development and Disease. (Under the direction of RUSSELL A. NORRIS) 
ABSTRACT 
        Non-syndromic Mitral Valve Prolapse (MVP) is a common disease with 
associated morbidities and mortality. Affecting 2-3% of the global population, 
MVP has become a significant health burden in developed countries.  
        We recently identified mutations in the cilia gene, DZIP1 in multiple 
families with MVP. To initially identify the function of DZIP1 in valve 
biology, we performed proteomics-based approaches with the goal of 
identifying unique binding partners for DZIP1. These studies revealed a direct 
interaction between DZIP1 and the β-catenin antagonist, CBY1. We 
hypothesized that DZIP1 suppresses the Wnt/ β-catenin pathway during mitral 
valve development through CBY1. Immunofluorescence staining revealed 
overlap between DZIP1 and CBY1 protein at the basal body of the primary 
cilium. Increase of activated β-catenin was observed in the Dzip1S14R/+ valves. 
Co-immunoprecipitation confirmed an interaction between DZIP1, CBY1 and 
β-catenin. Ensuing immunofluorescence staining suggested overlap between 
β-catenin and the basal body. DZIP1 truncation mutants identified a minimal 
CBY1 interaction motif within the C-terminus of DZIP1. A membrane 




as being able to interact with CBY1 and β-catenin. Treatment of chicken valve 
interstitial cells with the mimetic peptide resulted in significant decrease in 
activated nuclear β-catenin. To test whether this pathway was relevant in the 
context of the DZIP1 mutation, we assayed nuclear vs. cytoplasmic β-catenin 
expression in Dzip1S14R/+ MEFs. Western blot analysis showed a significant 
increase in nuclear β-catenin from the mutant cells. An additional family was 
identified with a rare DZIP1 variant within the DZIP1-CBY1 interaction motif. 
The mutation resulted in reduced DZIP1 and CBY1 protein stability and a 
peptide synthesized with the mutation resulted in an enhanced interaction 
between DZIP1 and β-catenin and an inhibitory effect on β-catenin signaling. 
Through analysis of nuclear β-catenin expression profiles during cardiac valve 
development, we conclude that Wnt/β-catenin signaling is temporally and 
spatially regulated. It is down regulated after E13.5 and undetectable in the 
adult. However, β-catenin signaling is significantly upregulated in human 
myxomatous valves and thus may be a major contributor to disease phenotype. 
        In conclusion, DZIP1 suppresses Wnt activity to direct mitral valve 
development through interacting with and stabilizing CBY1. This study 
characterizes the β-catenin expression profile during murine cardiac valve 
development and reveals a molecular mechanism, by which mutations in 




Altered β-catenin signaling may be an early initiating signal in the 








































1.1. Cardiac Valve Growth and Development 
1.1.1. Cardiac Valve Structure and Function 
      The four-chambered vertebrate heart has two sets of cardiac valves: the 
atrioventricular (AV) valves and semilunar (SL) valves. The AV valves, 
which include the mitral and tricuspid valves separate the atria and ventricles. 
The SL valves, which include the aortic and pulmonic valves separate the 
ventricles from the great arteries at the arterial pole[1].     
        The AV valves are made up of two (mitral) or three (tricuspid) valve 
leaflets, while the three leaflets of SL valves are named as cusps. The other 
difference between AV and SL valves, except for the leaflet’s name, is the 
supporting apparatus. AV valves are supported by chordae tendineae, which 
attach the valve leaflets to the ventricular papillary muscles[2]. The 
asymmetric leaflets are hinged to ring-raped annuli. A comparably unique 
supporting structure is present in aortic and pulmonic roots forming a fibrous 
annulus[3, 4]. Distinguished from AV valves annuli, the aortic valve annulus 
is crown-shaped giving rise to the “semilunar” shape of the individual 
cusps[5]. The names of the cusps are given by their relationship to the 
coronary artery ostia which are left, right and noncoronary cusps. Similar to 
AV valves, complete closure of the three cusps during diastole prevents blood 




valves open and close approximately 40 million times a year and 3 billion 
times over an average lifetime[6]. 
        Mature cardiac valves consist of complex stratified connective tissue 
which includes three different extracellular matrix layers (Figure 1.1). The 
layer termed the atrialis (AV) or ventricularis (SL) is predominantly 
composed of radially orientated elastic fibers. This layer provides assistance 
in valve tissue movement by allowing extension and recoil of the valve during 
the cardiac cycle[7]. The layer adjacent to atrialis (AV) or ventricularis (SL) 
is the spongiosa, which is primarily composed of proteoglycans, such as 
versican, decorin and biglycan. Proteoglycans in connective tissues serve for 
hydration, compliance, viscosity and regulation of collagen fibrillogenesis[8]. 
Their accumulation in tissues is associated with myxomatous degeneration[9]. 
Due to the compressible feature of proteoglycans, this layer provides a buffer 
region to absorb high force and allows for changes in leaflet shape during the 
cardiac cycle[10]. Adjacent to the spongiosa layer is the fibriosa layer, which 
is away from blood flow and located on the ventricular side of the AV valve 
leaflets and atrial side of the SL cusps. This layer is composed of densely 
packed collagen fibers, which provide strength and stiffness to maintain 
coaptation during diastole when back pressure stretches the valve leaflet or 




For example, collagen can be found in both atrialis and fibriosa[12], a network 
of elastic fibers also are present in spongiosa[13], and certain types of 
proteoglycan such as versican, decorin ,biglycan, tenascin are also observed 
in fibrosa and atrialis[13, 14]. The highly organized connective tissue system 
provides an indispensable biomechanical force for coping with the pressure 
stretches and compression imposed by the blood flow.  
        Besides ECM, the cells within the valvular tissue play a fundamental role 
in maintaining connective tissue homeostasis in the cardiac valvular functions. 
Similar to all the other blood-contacting cardiovascular system surfaces, the 
valves are lined by a layer of valvular endothelial cells (VECs) and packed 
with valvular interstitial cells (VICs).  
        VECs function in endothelial-to-mesenchymal transition during early 
valvulogenesis through transducing various signals have been elucidated 
profoundly while its roles in later stage still remain unclear[15-17]. The 
transformation of endothelial cells to mesenchymal cells requires the 
downregulation of intercellular adhesion junctions such as VE-cadherin. Pro-
EMT-inducing stimuli such as Tgf-β and Notch secreted from adjacent 
myocardium coordinate reprogramming of endothelial cells towards a 




such as Snail proteins are activated by Tgf-β and Notch and directly repress 
VE-cadherin expression by binding to promoters of VE-cadherin[18].  
        VICs are the most common cells in the valve and are composed of 
heterogeneous embryonic progenitor endothelial/mesenchymal cells, 
quiescent VICs (qVICs), activated VICs (aVICs), progenitor VICs and 
osteoblastic VICs[19]. Studies have shown that the heterogeneous behavior 
and expression of ECM demonstrated by VICs derived from different regions 
of valve tissue may be due to their diverse mechanical and extracellular 
environments in vivo[20-22].  
        The complex and well-defined ECM deposition as well as heterogeneous 
VICs give rise to the hints that diseased valvular tissues demonstrate altered 
ECM localization. The disturbed arrangement of connective tissue leads to 









Figure 1. 1 Overview of microarchitecture of adult cardiac valves  
 
Valve leaflets are composed of three layers of stratified extracellular matrix, 
including an elastin-rich ventricularis layer in SL valves (A) or the atrialis 
layer in the AV valves (B) shown as yellow, a proteoglycan-rich spongiosa 
layer shown as blue and a collagen-rich fibrosa layer shown as black. Valve 
tissue is sheathed in a monolayer of valve endothelial cells (VECs) and 
interspersed with valve interstitial cells (VICs). Mitral valve leaflet is 
supported by chordae tendinae, which attach leaflet to papillary muscles in 








Figure 1. 2 Diseased mitral valve is associated with disorganized ECM, 
disrupted VECs and altered VICs  
 
A. Well defined monolayer of VECs sheathing valve tissue and organized 
stratified ECM layers. B. Diseased mitral valve showing disrupted interspaces 
between ECM layers, disorganized VICs and interrupted VECs. Adapted from 






1.1.2. Endocardial cushion formation 
        During early vertebrate embryogenesis, the heart tube consists of an 
outer layer of myocardial cells and an inner lining of endocardial cells[23-27]. 
Specialized ECM composed of proteoglycans and glycosaminoglycans 
separates the myocardial and endocardial cell layers which is referred as 
cardiac jelly (CJ)[28]. Soon after rightward looping of the heart, the 
myocardium localized within specific regions of the primary heart tube, the 
atrioventricular canal (AVC) and outflow tract (OFT) increase ECM secretion, 
of which hyaluronan and chondroitin sulfates are the major components. This 
process gives rise to “swellings” of CJ into the lumen of the heart tube. Thus, 
the structure termed “endocardial cushion” is formed[1, 28-31]. The AVC or 
inlet connects atria and ventricles, and the OFT connects the ventricular 
outlets to the great arteries. Paracrine signals stimulate a subset of AVC and 
OFT endocardial cells to lose cell-cell contact, leading to their transformation 
into migratory mesenchyme. As a result, newly transformed mesenchymal 
cells seed the CJ separating endocardium and myocardium and proliferate to 
populate endocardial cushions. The process whereby subsets of AVC and 
OFT endocardial cells transform into a mesenchyme is called endothelial-to-




        Due to the EMT, the CJ between AVC and OFT becomes 
mesenchymalized and grows progressively into the lumen of the AVC and 
OFT as the primordium of future valve leaflets of the atrioventricular inlet 
(mitral and tricuspid valves) and the ventricular outlet (aortic and pulmonary 
semilunar valves). The fused atrioventricular cushions (AV cushions) lead to 
the eventual formation of the posteroinferior and septal leaflets of the tricuspid 
valve and the aortic leaflet of the mitral valve (anterior leaflet). During 
superior and inferior cushion fusion, the lateral cushions formed at the right 
and left AV junctions accounts for the development of anterior and posterior 
leaflets of tricuspid valve and the mural leaflet of the mitral valve[34, 35]. 
This radical event is dependent on myocardium derived soluble factors to 
signal the endocardium[36].  
        Formation of semilunar valves originates from cushion mesenchyme in 
the outflow tract. At 4-5 weeks of gestation, two big swellings in the truncal 
region (truncal cushion) and two small swellings in the conal region (conal 
cushion) develop in the outflow tract. The exact borderline between the 
truncal and conal cushion is almost unassessable in mammals. So, they are 
collectively termed conotruncal cushions. The mesenchyme of truncal 
cushions is mainly from neural crest cells, where the truncal mesenchyme then 




and pulmonary trunk. The mesenchymal conal cushions then merge to form a 
conal septum, separating the proximal OFT into the right and left ventricular 
outlets. The mesenchyme of conal cushions is derived from EMT of the 
endocardium, they give rise to the posterior right and left pulmonary valve 
cusps and to the anterior right coronary and left coronary aortic valve cusps. 
Adjacent to the conotruncal cushions are two other distinct cushions- the 
right-posterior and the left-anterior intercalated cushions. They develop 
respectively into the posterior noncoronary aortic valve cusps and anterior 
pulmonic valve cusps[37] (Figure 1.4).   
        The endocardial cushions not only give rise to valve structures but also 
contribute to the septation of the cardiac chambers. After endocardial cushions 
fuse across the midline of the AVC and proximal OFT, the junctional 
segments are divided anatomically into right and left or dorsal-ventral 









Figure 1. 3 Epithelial-to-mesenchymal transformation and valve elongation  
 
Endocardial cells in the AV cushions and conal cushions undergo endothelial-
to-mesenchymal transformation (EMT) and generate mesenchymal cells that 
populate the cushions. The mesenchymal cushions then remodel and elongate 
themselves to from primitive valves that mature into thin valve leaflets (shown 
here for the atrioventricular valves and the semilunar valves). Adapted from 































Figure 1. 4 Cardiac valves development 
Looping heart tube: During embryogenesis the cardiac valves develop 
through EMT of the endocardial cells. AVC cushion become AV leaflets 
and conotruncal cushion and intercalated cushions (not shown) become SL 
cusps. Mature heart: separated four chambers and AV/SL structure. Arrows 







1.1.3. Wnt signaling in cardiac EMT and valve morphogenesis 
The initiation of endocardial cushion EMT has been marked by 
activation of valvular endothelial cells (VECs) in response to a variety of 
signals derived from the adjacent networking myocardium[36]. Most of the 
signaling pathways crucial for early embryogenesis have been demonstrated 
to have an effect on endocardial cushion EMT, including transforming 
growth factor beta (TGF-β), WNT, and bone morphogenetic protein (BMP) 
ligands[1, 41-44]. This section is mainly focusing on Wnt/β-catenin signaling.  
        It has been asserted that Wnt signaling is used by cells to influence the 
fate or behavior of neighboring cells during development[45-48]. Wnt 
molecules are implicated in maintaining stem-cell-like fates in the interstitial 
epithelium[49], skin[50], hemopoietic cells[51] and promoting proliferation 
in AV cardiac cushion cells[52]. They are considered to signal through 
canonical and non-canonical pathways. 
        Canonical Wnt signaling has been investigated in a large number of 
developmental and disease processes. Simply speaking, a Wnt ligand is 
secreted and binds to and activates the Frizzled (FZD) class of receptors with 
low-density-lipoprotein receptor-related protein (LRP) on the cellular 




stabilization and nuclear localization of β-catenin and subsequently activates 
Wnt target genes in working with TCF/LEF1 family transcription factors[53]. 
In the absence of Wnt ligands, β-catenin is sequestered and phosphorylated 
by a degradation complex consisting of Adenomatosis polyposis coli (APC), 
AXIN, Glycogen synthase 3 β  (GSK3β ), and Casein kinase 1 (CK1). 
Phosphorylated β -catenin is targeted for degradation by the proteasome 
(Figure 1.5).           
        Upon Wnt stimulation, this GSK3β/AXIN/APC destruction complex is 
inactivated through phosphorylation and subsequently stabilizes β-catenin 
and releases it for entry into the nucleus. This pathway is critical for both 
endocardial cushion mesenchyme formation and later valve remodeling[18]. 
Studies in zebrafish revealed the contributions of Wnt/β-catenin signaling in 
determining endocardial cell fate. The apc mutant zebrafish hearts which had 
constitutive activation of the pathway failed to loop and form excessive 
endocardial cushions. Conversely, overexpression of Apc or Dickkopf 1 
(Dkk1), a secreted Wnt inhibitor, resulted in the block of cushion 
formation[42]. Studies in mice reinforce the observations in zebrafish that 




formation. The impairment of the β-catenin null cells to transform upon TGF-
β 2 stimulation implied a cross-talk between Tgf- β  and Wnt-signaling 
pathways during EMT[54]. However, this study did not clarify whether the 
loss of AV cushion mesenchyme in endothelial β-catenin (Ctnnb1)-null mice 
results from disrupted Wnt signaling or the distinct adherens junction role of 
β-catenin[55]. A recent study using inducible Tet-On transgenic system that 
provides spatiotemporal Wnt inhibition through Dkk1 expression suggested 
that canonical Wnt signaling is required for proximal outflow tract but not 
AVC cushion EMT. The loss of AVC cushions in endothelial β-catenin null 
mice is due to loss of adherens junctions. The Wnt signaling actually supports 
AVC cushion expansion as being required for AVC mesenchyme proliferation 
during EMT and enables mitral valve cushion mesenchyme to respond to 




















Figure 1. 5 Overview of Wnt/β catenin signaling  
 
In the off-state, or absence of Wnt, cytoplasmic β-catenin forms a complex 
with APC, Axin, CKI, and GSK-3 and then is targeted for proteasomal 
degradation while Wnt target genes are repressed by TCF/LEFs. In the on-
state, or presence of Wnt, a receptor complex forms between Frizzled and 
lipoprotein receptor-related protein families, which leads to accumulation of 
β-catenin in the cytoplasm and nucleus, where it serves as a coactivator for 
T CF/LEFs to activate Wnt-responsive genes. CK1, Casein kinase 1; GSK-
3, glycogen synthase kinase 3; TCF/LEF, T cell-factor proteins/ Lymphoid 
enhancer-binding factor; LRP, low-density-lipoprotein receptor-related 
protein; APC, adenomatous polyposis coli. Adapted from Evangelisti C, Int. 





        Another study by Hulin et al[57] using Axin2 knockout (Axin2LacZ/LacZ or 
Axin2-/-) mice offers significant advantage to study the role of canonical Wnt/
β-catenin signaling in valve homeostasis. Axin2 is an inhibitor of canonical 
Wnt/β-catenin signaling, the study showed hyperactivated Wnt/β-catenin 
signaling due to loss of Axin2 leads to progressive myxomatous ECM in mitral 
valves and aortic valve calcification. 
        Genetic studies from human myxomatous mitral valves suggested 
increases of multiple canonical Wnt/β-catenin signaling components 
including Wnt ligand (WNT9A), and receptor (FZD8), transcription factors 
(TCF4), and extracellular positive modulators of Wnt signaling (RSPO2), 
which is an Wnt/β-catenin signaling agonist through attenuation of DKK1-
dependent inhibition of Wnt ligands[58-60]. TGF-β2-treated human mitral 
valve interstitial cells (MVICs) demonstrated increased nuclear translocation 
of β-catenin while total protein levels stay unchanged in keeping with the prior 
study showing the cross talk between TGF-β and Wnt/β catenin signaling[54, 
60, 61]. 
        The other branch of Wnt signaling is the planar cell polarity (PCP) 
pathway, which is regulating the cells’ orientation relative to an axis along the 




non-canonical Wnt pathway. The core components of the pathway include 
transmembrane protein Frizzled, Vangl, Celsr and cytoplasmic proteins 
Prickle and Dvl[62]. Noncanonical Wnt ligands (Wnt5a and Wnt11) bind Fzd 
receptor and activate the recruitment of cytoplasmic Dvl to the plasma 
membrane to initiate downstream diverse pathways regulating different 
aspects of cytoskeleton reorganization in cell movements and polarity 
including RhoA, JNK, Profilin[62].  
        Normal cardiac development is dependent on PCP signaling, and the 
disrupted expression of proteins in PCP pathway contributes to heart defects. 
Loop-tail (Lp) mutations in Vangl2 abrogated its interaction with Dvl and 
results in outflow tract errors during development. Lp homozygotes mice 
manifested double-outlet right ventricle defects and double-sided aortic arch 
defects[63]. Mutations in Dvl2 gene show the similar OFT defects seen in Lp 
mice including double-outlet right ventricle and ventricular septal defects and 
the mechanism is thought to influence neural crest cell migration in PCP 
signaling[64]. More other studies have demonstrated that the rest PCP 
components are interfering the heart development, however, it is interesting 
to notice that no genes within the PCP pathway that cause cardiovascular 




fundamental role of PCP during very early gastrulation, and individuals with 
the mutations might be embryonical lethal[65]. 
1.1.4. Maturation of valve development 
                After formation of endocardial cushion is finished, EMT is stopped and 
VECs regain cell-cell contacts and get back an uninterrupted endothelium. At 
the same time, the connective tissue within the developing valve structures 
goes through extensive remodeling and cells continues to proliferate. The 
mature valve structure is made up of highly organized ECM that is 
sectionalized into three layers: the fibrosa, spongiosa, and atrialis (AV) or 
ventricularis (SL) as described in the first section. 
                The ECM of endocardial cushions before EMT is rich in hyaluronan, and 
the mesenchymal cells in the cushions start to produce collagens and matrix 
metalloproteinases (MMPs) 1, 2, 13, which promote cell migration[66-69]. 
The ECM composition of the mature valves is dependent of the synthetic 
activity of the VICs. Genes that encode fibrillar collagens, chondroitin sulfate 
proteoglycans and elastin are associated with the stratified ECM of the valve 
leaflets during the valve remodeling[3, 70]. At the molecular level during mid-
stages of valvulogenesis, loss of expression of mesenchymal-specific genes, 
including Twist1, Tbx20, Msx1, and Msx2, were observed in VICs. in vitro 




appear to have decreased differentiation potential as development progresses. 
Differentiation markers including Sox9 for chondrocyte and Scleraxis for 
tendon cells start to express in the VICs concurrently[71-74]. The complexity 
of ECM protein expression and stratification are the structural basis for valve 
function throughout life[10, 75]. Loss of the proteoglycan versican results in 
endocardial cushion maturation defects. Expressions of MMPs and their 
inhibitors, tissue matrix metalloproteinases (TIMPS) have been validated in 
the remodeling valves, and increased expression of several of these genes have 
been associated with human myxomatous valve disease as being observed 
with ECM disorganization[76-78].  
1.2. Primary Cilia 
1.2.1. structure and function 
        The primary cilium is a microtubule-based organelle that projects from 
the surface of the vertebrate cells[79]. Since as early as 1898 when primary 
cilium was first discovered, the primary cilium had long been ignored and was 
considered to be a vestigial remnant of evolution[80]. As intensive studies 
recently brought primary cilia into the spotlight, biologists have gained more 





        Sharing similar structure components with other types of cilia (motile 
cilia, nodal cilia), primary cilia demonstrate unique constructions which are 
closely tied to its function. Structurally, a primary cilium is composed of an 
axoneme and basal body. Generally speaking, most cells posse one cilium, an 
exception being olfactory sensory neurons where each cell possess about 10 
primary cilia[82]. The axoneme of a primary cilium contains a ring of nine 
outer microtubule doublets (known as 9+0 axoneme) which differs from 
motile cilium containing additional two central microtubule singlets 
surrounded by a ring of nine outer microtubule doublets (known as 9+2 
axoneme). Besides the central microtubule singlets, motile cilia possess 
dynein arms (outer and inner dynein arms) and radial spokes, the structures 
essential for and regulate cilium motility[83, 84]. The extension and 
maintaining of the axoneme are mediated by IFT (intraflagellar transport) 
machinery which transports various of particles along the axoneme. There are 
two trafficking systems defined by different compositions and trafficking 
directions. The anterograde IFT, moving from base toward cilium tip, is 
composed of kinesin-2 motor (contains KIF3A, KIF3B and KAP3) and IFTB 
proteins. While the retrograde IFT, moving from cilium tip toward the base, 
consists of dynein motor (DYNC2H1 and DYNC2L11) and IFTA 




during ciliogenesis. Perturbation of the anterograde IFT blocks cilia formation, 
however, disruption of the retrograde IFT leads to shortened cilia[85-89].   
        The basal body, a barrel structure of nine triplet microtubules, is derived 
from the mother centriole (Figure 1.6). During G1 phase, the centriole moves 
to the cell surface where it acts as a basal body to initiate ciliogenesis. Then, 
the cilia are resorbed during mitosis, and the basal body moves to the spindle 
pole and revert to centriole[90]. Basal bodies are absolutely required for 
ciliogenesis. One of the crucial functions is that basal bodies provide the 
template for the formation of the array of nine microtubule doublets of the 
axoneme. Studies showed that basal bodies that lost ninefold symmetry failed 
to propagate symmetry information to the axoneme, which had an effect on 
the doublets number in axoneme[91, 92]. It is also indicated by the electron 
micrographs that the outer doublet microtubules of the axoneme are 
contiguous with the triplet microtubules in the basal body[93]. In addition to 
acting as a template for microtubules, basal bodies also play a key role in 
membrane docking during ciliogenesis through ultrastructural features called 
transitional fibers by contacting the cell surface[90]. By forming centriole-
associated vesicles prior to the fusion with plasma membrane, the docking 
process is a specialized type of exocytosis[94]. Finally, basal bodies provide 




specialized structures at its distal end. Elongation of a growing cilium requires 
IFT cargo to transport ciliary proteins. Basal body contains recognition sites 
to recruit these assembly factors as evidenced by IFT accumulation around 
the basal body[95]. 
        Between axoneme and basal body is the transition zone, and transition 
fibers, collectively known as “ciliary gate” (Figure 1.6). Structurally, the 
transition zone includes Y-shaped links, ciliary necklace, and terminal plate 
(often visualized as an electron-dense aggregate on TEM). Y-shaped links act 
as connectors between microtubule doublets and primary cilia membrane 
microtubule doublets and primary cilia membrane. Ciliary necklace consists 
of several parallel strands of intramembrane particles separating terminal plate 
from plasma/cilia[96]. In motile cilia, the boundary between the axoneme and 
transition zone is referred to basal plate which is considered to participate in 
the nucleation of the central microtubules[97]. Because the lack of the central 
microtubules, primary cilia do not have this structure. It is proposed that the 
transition zone is to regulate ciliary protein composition in Chlamydomonas, 
C. elegans and mammalian cells through regulating the trafficking during 
ciliogenesis. However, the details of how the proteins are sorted have been 
undecided[98-100]. Transition fibers derive from basal body triplet 




They are thought to anchor microtubules to the plasm membrane through 
CEP164[101, 102] and ODF2. Also, transition fibers may play a role in 
docking the IFT and motor proteins required for ciliogenesis as evidenced by 
studies showing the localization of IFT52 on transition fibers[95]. 
        Being distinguished from architecture of axonemal microtubules, both 
motile and non-motile cilia are prevalently present in multiple tissues and 
organs throughout the body regulating key events during development and in 
the adult. Motile cilia are mainly used to move extracellular fluid and gametes. 
The motility is required to determine embryonic left-right asymmetry though 
a generation of extraembryonic fluid flow[103]. Motile cilia present on 
respiratory epithelial cells are contributing to mucus clearance[104]. 
Furthermore, the ependymal flow is also mediated by motile cilia[105]. On 
the other hand, primary cilia, lack of dynein arms and radial spokes, are 
fundamentally involved in chemo- and mechanosensory process that 
coordinate a variety of signaling pathways, such as the pathways mediated by 
Hedgehog (HH), G-protein-coupled receptors (GPCR), WNT, receptor-
















Figure 1. 6 Schematic representation of cilia ultrastructure  
 
Cilium is microtubule-based organelle structurally including axoneme, 
transition zone, transition fibers and basal body. On the middle part, is cross-
sections at axoneme in non-motile (Aka. Primary cilium) and motile cilium. 
Non-motile cilium has a 9+0 microtubule composition whereas motile cilium 
has a 9+2 microtubule composition possessing dynein arms, radial spokes. 
Ciliary motility of motile cilium is regulated by outer and inner dynein arms. 
On the left-hand side, is an enlarged immunofluorescence micrograph of a 
single primary cilium on an neonatal mouse mitral valve tissue for the cilia 
marker Arl 13b (red), the basal body marker γ-tubulin (green). Scale bar = 1 








1.2.2. Primary cilia in cardiac development 
        Expression of primary cilia in cardiac tissue during development is 
conserved across species[124]. Human embryonic and adult heart were also 
found to have primary cilia first by R Myklebust, et al in 1977[125]. Later on 
the spatiotemporal distribution of primary cilia during heart development have 
been described by showing the presence of primary throughout the E9.5 
embryonic mouse heart, lining the endothelium of both atrial primordia and 
persistence of primary cilia in the atrium and the ventricular trabeculation and 
epicardium at E12.5[126], yet no motile cilia were found in the embryonic 
heart through transmission electron microscopy (TEM)[127]. 
        The expression pattern of primary cilia during the mitral valves and 
aortic valves development have been demonstrated by our previous studies. 
Primary cilia were ubiquitously present in e11.5 mouse endothelial cushions. 
As AV cushions develop and stratify into valves, the number of primary cilia 
decreases and almost are absent on adult tissue (3 months). Whereas the 
primary cilia length increases and reaches its peak at P0[128]. During aortic 
valve development, primary cilia were present on the OFT cushions at E11.5. 
As development proceeds into fetal life, the number of primary cilia decreases, 




postnatally, similar to what have been observed in mitral valve tissue[129]. 
Interestingly, these studies about primary cilia spatiotemporal patterns have 
indicated that primary cilia were rarely seen on valve endocardium. The re-
absorption of cilia in the endothelium of the endocardial cushions is probably 
due to the fluid sheer stress as the biomechanical forces exerted by blood flow 
are sensed by the endothelium[130-134]. 
        The cilia length is a predictor of proper cilia function due to the findings 
of cilia function and several ciliopathies have been associated with defects in 
cilia length[135-137]. A number of ciliary genes affecting the elongation of 
primary cilia have been linked to congenital heart disease (CHD). Ift88, a 
component of the IFT system, is required for the formation and maintenance 
of primary cilia axonemes and has been studied extensively. Mice with Ift88 
mutations have defects in chamber maturation including atrial septal defects 
(ASD), ventricular septal defect (VSD), atrioventricular septal defect (AVSD), 
and OFT septal defects[126, 127, 138]. Furthermore, global loss of Kif3a, a 
component of kinesin-2 motor (refer to 1.2.1), results in complete lack of 
endocardial cushions[126] . In addition, targeted deletion of Ift88 
demonstrated a hypoplasia of endocardial cushions[138]. All these studies 
suggest that primary cilia are involved in formation and development of 




        Studies from our group demonstrated that conditional ablation of Ift88 
with NfatC1 Cre which knocked out Ift88 exclusively from endocardial and 
endocardial derived cells results in myxomatous mitral valve disease and 
bicuspid aortic valves (BAV). The mechanism is still not quite clear, but the 
RNA-seq analysis confirmed that loss of primary cilia results in robust 
activation of ECM gene pathways. Subsequent IHC showed altered ECM 
expansion and deposition in Ift88 deficient valve tissue. These observations 
highly suggest that primary cilia are likely to impact valvulogenesis through 
restraining ECM production[128, 129].  
1.2.3. Wnt signaling and primary cilia  
                 The Wnt signaling network is critical to valve development. As 
discussed above, either up or down-regulated Wnt/β-catenin signaling leads 
to morphological change during valvulogenesis. With more and more ciliary 
proteins being identified to paly roles in Wnt/β-catenin signaling, there has 
been a controversial argument about the link between Wnt signaling and the 
primary cilium. 
                Among them, Dvl regulates activation of the canonical pathway through 
inhibiting GSK3β/Axin/APC complex. In this way, Dvl protects β-catenin 
from being degraded by proteasome. Early studies showing Inv localized to 




Wnt pathway[139-141]. Following research using Wnt-responsive reporter 
construct suggested that Inv abrogated the ability of Dvl to activate Wnt 
signaling. These studies indicate that canonical Wnt signaling is actually 
constrained rather than promoted by events at cilia[140]. Disruption of 
primary cilia in mice containing mutations in Kif3a, Ift88 or Ofd1 (an X-
linked gene encoding a basal body protein required for ciliogenesis[142]) 
resulted in a remarkable increase in cellular response to canonical Wnt 
signaling in both cultured mouse embryonic fibroblasts (MEFs) and 
embryonic stem cells[143]. However, confounding results were observed in 
Ahi1 mutant mice, which showed a loss of basal canonical Wnt signaling 
activity resulting in cystic kidney disease[144]. AHI1 in humans encodes 
Jouberin, a cilia protein, mutation of which causes a severe multi-organ 
ciliopathy including polycystic kidneys[145]. This study might seem to 
indicate a positive, rather than negative role for cilia in Wnt signaling. 
                Some studies argue that there is in fact no role at all for cilia in Wnt 
signaling. The study in ift88 mutant zebrafish did not show apparent defects 
in Wnt-dependent developmental processes or in expression of known Wnt 
target genes while did display the absence of primary cilia[146]. The Ift88, 
Ift172, Kif3a and Dync2h1 mutant mice embryos did not show distinguishable 




transgenic mouse embryo to report canonical Wnt signaling in those mutants 
did not show β-galactosidase expression patterns alterations, either[147]. The 
Wnt reporter quantification in MEFs generated from wildtype and cilia-
defective mice did not find any difference in the response to Wnt ligand, as 
well[147]. From the confounding studies, it is very much clear that regulatory 
role of canonical Wnt signaling from primary cilia is cell type specific. It is 
drastically more subtle than the role of cilia in other signaling pathways, such 
as Hh signaling[148]. 
        Additional researches about roles of cilia upon non-canonical Wnt 
signaling (PCP) add a further layer of complexity to relationship between cilia 
and Wnt signaling. Multiple PCP components are localized to basal body such 
as Vangl2 and Dvl2, of which defections result in OFT and ventricular defects 
as discussed previously[63, 64, 149]. In support of the idea that non-canonical 
Wnt signaling is associated with cardiac primary cilia, ciliary genes such as 
Gmap210 was deleted in mice embryos. GMAP210 functions with IFT20 in 
the trafficking of ciliary proteins for ciliogenesis. The model demonstrated 
cardiac phenotypes resembling those observed in multiple PCP mutants[150]. 
But this is not direct evidence that the cardiac phenotypes observed in the 
Gmap210-/- mouse are associated with defective non-canonical Wnt signaling. 




orientation of basal bodies involved in the establishment of left-right 
asymmetry during embryogenesis[151-153]. However, as PCP components 
are also required for basal body assembly/docking, a key question that 
remains to be determined is what is required first: intact PCP signaling for 
ciliogenesis/basal body positioning, or intact cilium for subsequent PCP 
events? Another question that needs to be elucidated is whether the cilium is 
responsible for the phenotypes observed in some PCP mutants. Since many of 
the ciliary proteins have now been identified in other cellular locations. These 
ciliary proteins could be necessary for some other cellular functions. For 
example, the basal body protein CBY1 has been reported to directly regulate 
β-catenin signaling[154]. 
1.3. Mitral valve Disease 
1.3.1. Anatomy 
        As discussed in the first section that mitral valve (MV) apparatus is a 
complex structure composed of the annulus, leaflets, chordae tendineae, and 
papillary muscles[155-158]. Detailed anatomical features of MV will be 
illustrated here. 
        The MV annulus is a support compartment in continuity with the aortic 
valve through the fibrous aortic-mitral curtain. The two mitral leaflets meet at 




from lateral to medial—in the human. There are two dominant papillary 
muscles attached to MV leaflets via chordae tendineae, one anterolateral and 
the other posteromedial. Anterolateral papillary muscles engaging in dual 
blood supply while posteromedial only has single blood supply which are 
more prone to injury from myocardial infarction. The fibrous chordae 
tendineae are divided into three types based on their insertion level: primary 
chordae insert on the leaflet tips functioning to maintain coaptation of leaflets, 
the secondary chordae insert on mid-body of the leaflets providing support 
length to leaflets, and the tertiary chordae insert only on the basal part of the 
posterior leaflet functioning as structural support. Any pathological alterations 
at any level of the MV apparatus can lead to MV dysfunction.  
1.3.2. Mitral valve pathology 
1.3.2.1. Mitral valve stenosis 
        MV dysfunction contains mainly two types: MV stenosis (MS) and MV 
regurgitation. The most common cause of mitral valve stenosis world-wide is 
rheumatic heart disease (RHD). It is considered to be associated with an 
exaggerated immune response initiated by cross-reactivity between a 
streptococcal antigen and the valve tissue[159]. Although it is less common 
in western countries, it remains a major public health issue in developing 




disorders such as lupus erythematous and rheumatoid arthritis, congenital 
causes such as parachute mitral valve, double-orifice mitral valve, or 
supravalvular mitral ring[161].  
1.3.2.2. Mitral valve regurgitation 
The most common cause of mitral valve regurgitation (MR) requiring 
surgical intervention in developed countries is MV prolapse (MVP)[161]. 
MVP can be classified into syndromic and none-syndromic MVP. Syndromic 
MVP affect the connective tissue, such as Marfan syndrome, Ehler-Danlos 
syndrome, osteogenesis imperfecta and pseudoxanthoma elasticum, which 
result from genetic mutations associated with ECM homeostasis. MVP is one 
of the manifestations among multiple system impacted symptoms[161]. Non-
syndromic MVP, which primarily affects mitral valve, results from 
myxomatous degeneration characterized by abnormal accumulation of 
proteoglycan, collagen fragmentation and hyperactivated fibroblast[162]. 
Over time, leaflets become thickened and floppy which may billow into left 
atrium during cardiac systolic cycle. On echocardiography, MV prolapse is 
defined as an abnormal leaflet systolic displacement of ≥2 mm above the 
mitral annulus plane in a long-axis view[163]. The bulging leaflet gives rise 




resulting in mitral regurgitation which causes left atrial and left ventricular 
volume overload. 
Based on the time course of the development of the regurgitation, MR is 
divided into acute MR and chronic MR. Acute MR may culminate in 
cardiogenic shock due to significantly declines of forward output since much 
of the flow is directed to the left atrium. Also, the sudden marked increase in 
preload results in a significant increase in LV filling pressures which are 
transmitted to the pulmonary circulation leading to pulmonary edema. 
Chronic MR has a longer progression from early compensated stage to a 
decompensated stage marked by the development of symptoms. Long-term 
regurgitation leads to the enlargement of LA, which forms the nidus for the 
development of atrial arrhythmias[164].  
1.4. Genetic Discoveries in MVP 
MVP is a common cardiac valvular disorder that affects about 2%-3% 
of the general population and predisposes the affected individual to a greater 
risk for MR, arrhythmia and sudden cardiac death as discussed in previous 
section[165-167]. Increased understanding of valvular development, in 
combination with current advances in genome-wide association studies, has 




The first discovery of genetic basis of MVP in humans has occurred 
through investigation of Marfan syndrome which gives rise to syndromic 
MVP[168]. Mutations in Fibrillin 1 (FBN1), a crucial content of ECM 
microfibrils, have been discovered to cause Marfan syndrome[169-171]. 
Subsequent studies elucidated the molecular mechanism that FBN1 limits the 
activation of TGF-β signaling, excessive activation of which leads to ECM 
remodeling in the embryonic development of valves[172]. Mouse model 
carrying a C1039G mutation in Fbn1 exhibit thickened valves phenocopied 
the myxomatous valves in human which was rescued by Tgf-β antagonism 
supporting the role for Tgf-β signaling in MVP[173].  
Not only in Marfan’s syndrome, MVP appears in other connective tissue 
dysplasia such as Ehlers-Danlos (EDS), Stickler, and osteogenesis imperfecta 
suggesting the association between genetic mutation of collagen genes and 
etiology of MVP. The family of collagen genes found in human valvular 
disease to date includes Collagen types I-III, V and XI[174]. 
        By studying families with inherited non-syndromic MVP, three genes 
that are associated with MVP have been identified. The first gene linked to 
non-syndromic myxomatous valve disease in humans is Filamin A 




relation of FLNA to X linked MVP was documented by additional four 
families[176-179]. FLNA is a structural cytoplasmic protein in the 
cytoskeleton and interacts with cell-surface integrins[175]. Expression of 
FLNA in the endocardium, epicardium and interstitial cells of the valves have 
been characterized, and mouse study with Tie2-Cre confirmed that loss of 
endothelial FLNA results in myxomatous mitral valves[180]. In 2015, a loss-
of-function mutation in the DCHS1, which encodes a member of the cadherin 
superfamily and critical for PCP, was identified. This mutation reduces 
protein stability and Dchs1+/- mice develop thickened and prolapse mitral 
leaflets[181]. The third gene mutation was identified in DZIP1, which is both 
essential for ciliogenesis and for Hh signaling[128, 182]. Knock-in mice 
manifested myxomatous mitral leaflets which phenocopied human MVP and 
ciliopathy indicating that primary cilia contribute to the MVP disease 
pathogenesis[128].  
        In 2015, Dina et al identified the first 3 risk loci for MVP by performing 
a meta-analysis of 2 genome-wide association studies in 1412 MVP cases and 
2439 controls[183]. Among the genes located within the associated 
haplotypes, they identified LMCD1 (Lim and cysteine-rich domains 1), 
knockdown of which in zebrafish resulted in increased AC regurgitation and 




knockout of which in mice caused enlarged posterior mitral leaflets. This 
study suggests new mechanisms involved in MVP regurgitation development.  
1.5. Summary 
        Cardiac valve development is a complex process involving multiple 
signaling pathways. This thesis work is mainly focusing on the canonical 
Wnt/β-catenin signaling. As discussed in 1.2.3, Wnt/β-catenin signaling 
pathway is indispensable for AVC cushions mesenchymal proliferation and 
for OFT EMT. A variety of Wnt signaling components are increased in 
myxomatous valve degeneration. Hyperactivation of Wnt/β-signaling during 
cardiac valve give rise to myxomatous degeneration. All these evidences 
suggest the importance of well-controlled Wnt/β-catenin during cardiac valve 
development. But the regulation of the signaling during valvulogenesis has 
not been profoundly investigated. The basic question that how β-catenin 
distributes during valve development is still not clear. The Chapter 2 of this 
thesis work is to clarify the expression profile of β-catenin during murine 
valve development. Since membrane bound β-catenin accounts for cell-cell 
adhesion, yet nuclear bound β-catenin is responsible for gene transcription, it 
is crucial to separate them when considering the roles of β-catenin during 
valvulogenesis. This characterization provides a platform where future studies 




        Genetic analysis within non-syndromic MVP give rise to valuable clues 
in etiology of MVP. One of the genetic mutations that has been validated to 
cause myxomatous valve degeneration so far is DZIP1. 
Immunohistochemistry study on myxomatous valve in Chapter 2 revealed 
overexpression of β-catenin. To explore how Dzip1 involves in the β-catenin 






















Chapter 2: Dynamic Expression Profiles of β-Catenin during Murine 
























        β-catenin is a multifaceted protein with various functions based on its 
subcellular localization[184-188]. Expression studies have demonstrated its 
presence on the cell membrane, free within the cytoplasm and in the 
nucleus[189-193]. Its subcellular functions are likely driven by conserved 
structural motifs within the protein, which confer unique protein-protein 
interactions[194-196]. The basic protein organization of β-catenin consists of 
an amino terminal domain, a central region consisting of 12 Armadillo repeats 
and a carboxyl-terminal region[197, 198]. Through the Armadillo repeats, β-
catenin serves as both a structural scaffold and signaling protein for a 
multitude of interaction partners in adherens junctions, the cytoplasm as well 
as the nucleus[199-203].  
        At the level of the membrane, β-catenin was initially discovered as being 
associated with E-cadherin, a critical protein essential for Ca2+-dependent 
cell-cell adhesions[204-206]. Through these cadherin-catenin interactions the 
adherens junctions become stabilized[207-209]. Upon receiving a Wnt 
signaling and/or phosphorylation of β-catenin at specific residues, this 
interaction is disrupted, and β-catenin is released from its junctional 
components[210-212]. The fate of β-catenin following this release is complex 




214]. Although β-catenin does not contain an import or export signal, its 
nuclear presence can be driven by either protein chaperones or its binding to 
nuclear pore complexes[215-217]. Within the nucleus, β-catenin has been 
shown to regulate many aspects of nuclear biology. Most routinely analyzed 
are its ability to interact with co-transcription factors in the TCF/LEF1 gene 
family[218-220]. It is, however, becoming clear that β-catenin can have 
unique TCF/LEF1 independent functions in the nucleus including the 
regulation of chromatin remodeling as well as inducing or repressing gene 
transcription through association with other co-factors[221-225]. Through the 
complexities of the structural and signaling roles of β-catenin, it is no surprise 
that perturbation of its expression can impact many different tissues in various 
ways. For example, gain and loss of function studies in the heart have revealed 
a critical role for β-catenin in cardiac development, especially related to valve 
morphogenesis[56, 226].  
        Although heavily studied, a more thorough characterization of the 
expression and localization of either nuclear or membrane β-catenin 
throughout cardiac development has yet to be reported. Additionally, scant 
data have been shown that clarify the correlation of Lef1 and nuclear β-catenin 
at different gestation stages. This information is needed to inform various 




analysis of β-catenin’s temporal, cell-specific subcellular protein expression 
pattern is the focus of this chapter. Herein we report a detailed β-catenin 
expression map within the heart, which will facilitate proper interpretation of 
gain and loss of function data as well as provide new insight into fundamental 

































        β-catenin expression during embryonic cardiac development 
        IHC staining for both activated (β-cateninpS552) and membranous β-
catenin revealed dynamic staining patterns that are spatially and temporally 
regulated during embryonic gestation. At E11.5, activated β-catenin is 
ubiquitously expressed in the nuclei of virtually all cardiac cells including 
myocardium, epicardium, endothelium and aortic and atrioventricular valve 
progenitor cells (Figure 2.1A-D). A slight, yet consistently lower IHC 
intensity of activated nuclear β-catenin expression was observed where the 
superior and inferior AV cushions fuse (Figure 2.1D-arrows). In the outflow 
segment, activated β-catenin is observed throughout the myocardium and 
outflow tract cushions (Figure 2.2E-H). Within the myocardial sleave of the 
outflow tract, the cell membrane of myocytes also stained positive for 
activated β-catenin (Figure 2.2G, H-arrowheads). This staining seemed 
specific for the conotruncal myocardium as no other myocardial regions 








Figure 2. 1 Activated β-catenin expression at E11.5 inflow AV cushions. 
Representative images of E11.5 inflow AV cushions immunostained for 
activated β -catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with hoechst (blue). Myo=Myocardium, 








Figure 2. 2 Activated β-catenin expression at E11.5 outflow tract cushions. 
 
Representative images of E11.5 outflow tract cushions immunostained for 
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained for hoechst (blue). CC=conal cushions, TC=truncal cushions, 
arrows=endocardium within outflow tract, arrowheads=myocardium within 









Much like activated nuclear β-catenin expression, non-phosphorylated 
membrane β-catenin was also extensively observed throughout the heart at 
E11.5 (Figure 2.3 & Figure 2.4). Within the developing atrioventricular and 
outflow tract cushions, membrane β-catenin was observed in the endocardial 
and interstitial mesenchyme. Within these structures, the highest degree of 
intensity was observed nearest the cushion endocardium. However, in areas 
where the major cushions fuse, both PECAM, the adherens junctions marker, 
and β-catenin expression appeared dysregulated and with reduced staining 
intensity (Figure 2.3D-arrowheads). This was similar to the pattern of 
membrane β-catenin in the conal cushions in which the endocardial 
epithelium displayed lower staining intensity (Figures 2.4E, F, and G- 
arrowheads). Membrane expression of β-catenin was prominent in all 











Figure 2. 3 Non-phosphorylated β-catenin expression at E11.5 inflow AV 
cushions. 
Representative images of E11.5 inflow AV cushions immunostained for non-
phosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with hoechst (blue). MYO=myocardium, 
AVC=atrioventricular cushions, arrows=endocardial cells with less IHC 








Figure 2. 4 Non-phosphorylated β-catenin expression at E11.5 outflow tract 
cushions. 
Representative images of E11.5 outflow tract cushions immunostained for 
non-phosphorylated β-catenin (red), MF (green), PECAM (green) and nuclei 
counterstained with Hoechst (blue). CC=conal cushions, epi=epicardium, 








        By E13.5, although expression within the mesenchymal cells of the AV 
valves is still evident, expression of activated nuclear β-catenin appears 
reduced with evidence of perinuclear or membrane expression, especially 
within the AV valve endocardium (Figure 2.5B, D- arrowheads). 
Additionally, many interstitial cells within the AV valves failed to exhibit 
detectable activated β-catenin (Figure 2.5B, D- arrows). Valve interstitial 
cells closest to the AV valve endocardium appear to have lost or greatly 
downregulated expression of activated β-catenin as nuclear expression is 
primarily restricted to a core group of cells within the valve (Figure 2.5 B, D-
dotted line). Downregulation of activated nuclear β-catenin was not specific 
to the AV valves as we also observed this expression change in the developing 
semilunar valves of the outflow tract (Figure 2.6E-H). However, within the 
outflow tract valves, expression of activated β-catenin was almost completely 
confined to the valve endocardium with only a few interstitial cells staining 
positive. Within valve endocardial cells, punctate, nuclear expression was 
evident as well as its presence on the cell membrane (Figure 2.6F – boxed 
region). Within the E13.5 myocardium activated β-catenin was evident within 
the nuclei as well as on the cell membrane. Thus, within the heart at E13.5, a 
change in subcellular localization of activated β-catenin is evident as 




protein is observed. In addition, our stainings reveal a profound 
downregulation of the phosphorylated, activated form of β-catenin within the 
developing mitral and aortic valves. 
        As our data showed reduced nuclear β-catenin activation at E13.5, we 
tested whether expression of non-phosphorylated β-catenin showed a 
concurrent up-regulation and/or prominence at the cell membrane. As shown 
in Figure 2.7 &Figure 2.8, membrane β-catenin was robust in all areas of the 
heart analyzed. The endocardium and subendocardial mesenchyme within the 
E13.5 atrioventricular (AV) valves displayed prominent membrane β-catenin 
staining. (Figure 2.7A-D). The graded staining pattern within the AV valves 
appeared similar to that observed at E11.5, albeit more pronounced at E13.5. 
The dotted lines in Figures 2.7A-D demarcate this unique spatial boundary 
between two apparent different cell phenotypes based on membrane stainings 
for β-catenin. Within the central mass of the valves there appears to be a core 
of interstitial cells that display uneven distribution of β-catenin staining. This 
is converse to the circumferential, staining of the endocardial and 
subendocardial mesenchyme. Much like at E11.5 (Figure 2.3), this pattern of 
uneven distribution of staining possibly demarcates an interstitial cell type 
that is more primitive and/or shares a phenotype consistent with a less mature 




membrane is observed within the outflow tract mesenchyme of the semilunar 
valves. One noticeable difference is that the majority of the interstitial 
mesenchyme in these valves do not display circumferential β-catenin 
expression, but rather a punctate pattern (Figure 2.8F-boxed region). The 
outflow tract valve endocardium shows membrane expression of β-catenin 
along the basal aspect of these cells, consistent with the presence of adherens 
junctions (Figure 2.8F, H-arrows). Within the left coronary cusp, many of the 
interstitial cells had very low to undetectable expression of β-catenin (Figure 
2.8E-H-asterisks). Outside of the valves, membrane expression of β-catenin 
was robust in all areas observed including on cardiomyocytes, the epicardium, 
aortic wall and ventricular endocardium. 
        These expression data correlate with a time point of robust growth within 
the heart, consistent with a previously identified role for β-catenin in 
proliferation events. It is interesting to note that the endocardium of AV and 
conal cushion tissue that are destined to fuse at E11.5 show disorganized or 
reduced expression of both membrane and nuclear β-catenin, suggesting that 
downregulation of the protein may be required for differentiation of these cell 
types or may represent a consequence of compressive mechanical forces 
known to occur at these areas. Consistent with this concept of differentiation 




observed at E11.5 and E13.5. Alternatively, the difference in staining intensity 
could simply represent a different ultrastructural phenotype of the cell 
membrane within the valve interstitium. Previous reports by us and others 
have shown that subendocardial cushion mesenchyme are denser compared to 
the more dispersed interstitial cells proximal to the myocardium, thereby 
likely demarcating at least two different cell types within the AV cushions at 
this stage of development. The difference of staining pattern and intensity 










Figure 2. 5 Activated β-catenin expression at E13.5 inflow AV valves. 
Representative images of E13.5 inflow AV valves immunostained for 
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with Hoechst (blue). AL=anterior leaflet, PL=posterior leaflet, 










Figure 2. 6 Activated β-catenin expression at E13.5 outflow tract SL valves. 
 
Representative images of E13.5 outflow tract SL valves immunostained for 
activated β-catenin (red), MF20 (green), PECAM (green) and nuclei 









Figure 2. 7 Non-phosphorylated β-catenin expression at E13.5 inflow AV 
valves. 
Representative images of E13.5 inflow AV valves immunostained for non-
phosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with hoechst (blue). AL=anterior leaflet, PL=posterior leaflet, 








Figure 2. 8 Non-phosphorylated β-catenin expression at E13.5 outflow tract 
SL valves. 
 
Representative images of E13.5 outflow tract SL valves immunostained for 
non-phosphorylated β-catenin (red), MF20 (green), PECAM (green) and 
nuclei counterstained with Hoechst (blue). RA=right atrium, Ao=aorta, 
LA=left atrium, RC=right coronary, LC=left coronary, 








        β-catenin expression during fetal cardiac development 
        Immunohistochemical stains were performed for both activated (β-
cateninpS552) and non-phosphorylated β-catenin during fetal cardiac 
morphogenesis at E17.5. Within the mitral valves, activated β-catenin was 
observed in the nuclei of some cells in a spatial pattern similar to what was 
observed at E13.5 (Figures 2.5A-D and 2.7A-D) with some slight, 
differences. Within the belly of the mitral leaflets, most interstitial cells 
exhibited either undetectable or low levels of β-catenin nuclear expression. 
Some, but not all, mitral valve endocardial and subendocardial interstitial cells 
displayed weak expression of nuclear β-catenin (Figure 2.9B, D). This pattern 
of expression within the valves is reminiscent of the proteoglycan rich 
spongiosa region of the mitral valve. Co-immunostains of activated nuclear 
β-catenin with hyaluronan binding protein confirmed that nuclear β-catenin is 
primarily restricted to this particular valvular region at both E17.5 and E13.5 
(Figure 2.18). Within the aortic valves, activated β-catenin was only observed 
in a few cells within the hinge regions connecting the aortic cusps to the aortic 
wall (Figure 2.10F-arrows). Additionally, a few cells along one side of the 
right coronary cusp were positive for nuclear β-catenin expression (Figure 




would support a continual, gradual downregulation of nuclear β-catenin 
during gestation. 
        Regions outside of the mitral or aortic valves showed prominent nuclear 
β-catenin staining including the primary atrial septum, the myocardial rim 
lining the mitral-aortic continuity and the inter ventricular septum (Figure 2.9 
& Figure 2.10). The myocardium of the left atrium also appears to be positive, 
albeit at a much lower staining intensity than the adjacent left ventricular wall 
(Figure 2.9C). Within the left ventricular wall, we noticed that nuclear β-
catenin within the distal/posterior basal myocardium showed robust staining, 
yet in more proximal sections this staining was largely absent (Figure 2.10G-
arrow). Within the proximal/anterior heart regions, expression is observed 
within the myocardial reflections adjacent to the aortic wall (Figure 2.10G-
arrowhead). These data suggest that β-catenin expression within the left 
ventricular myocardium is non-uniform and may demarcate either different 
cell populations or spatially dependent functional requirements for these cells. 
        The staining for membrane-bound, non-phosphorylated β-catenin at 
E17.5 exhibited a much different pattern than observed for the nuclear form, 
especially within the aortic valves (Figure 2.12). Within the anterior and 
posterior mitral leaflets, membrane β-catenin was expressed prominently 




adjacent to the atrialis endocardium of the mitral leaflets displayed positive 
staining with much less, to undetectable expression within the rest of the 
mitral leaflets (Figure 2.11D-arrowheads). Within the aortic valves, 
widespread membrane β-catenin was evident on all endocardial cells and most 
interstitial cells (Figure 2.12E-H). Unlike the activated form of β-catenin, low 
to undetectable membrane staining was evident on interstitial cells within the 
hinge regions (Figure 2.12H-boxed region). Unlike the mitral valve, the 
staining within the aortic valve does not appear to be confined to one 
particular cell layer within the valve cusps. Outside of the mitral and aortic 
valves, membrane expression is observed in most cell types including 
ventricular endocardium and myocardium and on myocytes within the mitro-
aortic continuity (MAC) (Figure 2.12E-G). Membrane β-catenin was 
undetectable on epicardial cells within the left ventricle or within the 










Figure 2. 9 Activated β-catenin expression at E17.5 mitral valves. 
Representative images of E17.5 mitral valves immunostained for activated β-
catenin (red), MF20 (green), PECAM (green) and nuclei counterstained with 
hoechst (blue). LA=left atrium, PL=posterior leaflet, AL=anterior leaflet, 









Figure 2. 10 Activated β-catenin expression at E17.5 aortic valves. 
 
Representative images of E17.5 aortic valves immunostained for activated β-
catenin (red), MF20 (green), PECAM (green) and nuclei counterstained with 
hoechst (blue). Ao=aorta, LC=left coronary, RC=right coronary, LV=left 









Figure 2. 11 Non-phosphorylated β-catenin expression at E17.5 mitral valves. 
 
Representative images of E17.5 mitral valves immunostained for non-
phosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with hoechst (blue). Epi=epicardium, PAS=primary atrial 
septum, LA=left atrium, LV=left ventricle, AL=anterior leaflet, PL=posterior 








Figure 2. 12 Non-phosphorylated β-catenin expression at E17.5 aortic valves. 
Representative images of E17.5 aortic valves immunostained for non-
phosphorylated β-catenin (red), MF20 (green), PECAM (green) and nuclei 
counterstained with Hoechst (blue). Ao=aorta, LC=left coronary, RC=right 
coronary, AL=anterior leaflet, PL=posterior leaflet, MAC=mitro-aortic 








        Postnatal cardiac β-catenin expression 
        As either loss of or gain of function of β-catenin has been shown to 
contribute to cardiac valvular diseases and postnatal cardiac regenerative 
processes, we sought to evaluate expression of β-catenin after birth. As shown 
in Figure 2.13, activated β-catenin is only present within a subset of mitral 
valve interstitial cells confined to the tips at neonatal timepoints. The mitral 
valve endocardium is mostly devoid of positive nuclear staining (Figure 
2.13A, B). On the contrary, membrane staining for β-catenin is robust in the 
mitral valve endocardium and co-labels with CD31/Pecam at adherens 
junctions (Figure 2.13D, E). In adult mice no detectable nuclear β-catenin is 
observed within the mitral leaflets whereas the non-phosphorylated β-catenin 
isoform is present primarily along the valve endocardial lining of the atrialis 
(Figure 2.14). Consistent with previous reports, nuclear β-catenin is 
undetectable within the IVS myocardium (Figure 2.14 left), but the non-
phosphorylated isoform is observed within the intercalated discs of 
cardiomyocytes (Figure 2.14-boxed region). The aortic valves show a similar 
pattern for β-catenin expression compared to the mitral valves, with one 
exception (Figure 2.15 & Figure 2.16). While membrane bound β-catenin 
co-localizes with CD31/Pecam within the aortic valve endocardium as well as 




arrows), we fail to detect the presence of nuclear β-catenin within the aortic 
valves (Figure 2.15 G, H). Similarly, neither form of β-catenin is observed in 
the adult aortic valve leaflets (Figure 2.16). At the postnatal timepoints we do 
not observe β-catenin expression within the hinge regions of the aortic cusps 
but do observe membrane staining within the aortic wall (Figure 2.15 J, K-
asterisks). These data demonstrate that activated nuclear β-catenin expression 
is only detectable during a developmental and early neonatal window, 
whereas membrane bound β-catenin continues throughout life, at least in the 
















Figure 2. 13 β-catenin expression at neonatal mitral valves. 
Representative images of P0 mitral valves immunostained for both forms of 
β-catenin (red), MF20 (green), PECAM (green) and nuclei counterstained 








Figure 2. 14 β-catenin expression at adult mitral valves. 
Representative images of 6-month mitral valves immunostained for activated 
β-catenin (red), MF20 (green) and nuclei counterstained with hoechst (blue). 














Figure 2. 15 β-catenin expression at neonatal aortic valves.  
Representative images of P0 aortic valves immunostained for both forms of 
β-catenin (red), MF20 (green), PECAM (green) and nuclei counterstained 
with hoechst (blue). RC=right coronary, LC=left coronary, Ao=aorta, 








Figure 2. 16 β-catenin expression at adult aortic valves.  
Representative images of 6-month aortic valves immunostained for both 
forms of β-catenin (red), MF20 (green) and nuclei counterstained with hoechst 














        Correlation of β-catenin activities with Lef1 
        Activated β-catenin can enter the nuclei and bind TCF/LEF transcription 
factor to activate transcription of downstream target genes[209, 218, 227]. 
Therefore, Lef1 is commonly used as a readout marker for β-catenin signaling 
[228-233]. More recently, the existence of β-catenin-independent functions 
for Lef1 have been documented, bringing into question whether lef1 reporters 
represent physiologically accurate measures of β-catenin signaling. To test 
this concept, we co-stained activated β-catenin with Lef1 on mitral valve 
tissues during embryonic and fetal gestation to determine if they co-localized 
with each other (Figure 2.17). During embryonic timepoints, most of the Lef1 
positive stained cells were co-stained with nuclear β-catenin. However, a 
major discrepancy at this timepoint was that Lef1 was positive only in a subset 
of cells, indicating a lef1-independent nuclear role for β-catenin. The staining 
at E17.5 showed an even more striking discrepancy between Lef1 and nuclear 
β-catenin staining. Lef1 positive cells were observed within nuclei of mitral 
valve interstitial cells localized to the tip of the leaflets. However, these 
positively stained Lef1 cells showed little detectable β-catenin staining 
(Figure 2.17 I-arrows). We rarely observed valve endocardial cells that co-
stained with both markers (Figure 2.17 I-arrowhead). These data support the 




and β-catenin, the majority of their activities are not mutually inclusive; likely 












Figure 2. 17 Correlation of β-catenin activities with Lef1. 
(A-F). Activated β-catenin (green) and Lef1 (red) were co-stained on E11.5 
tissue. Only a subset of activated β-catenin positive cells was co-stained with 
Lef1. (G-I) Co-staining Lef1 with activated β-catenin at E17.5. Lef1 positive 
cells were localized to the tip of the leaflets showing no appreciable β-catenin 
staining (G, I-arrows) and valve endocardial cells that co-stained with both 
markers were rarely observed (I-arrowhead). AVC= atrioventricular 
cushions, myo= myocardium, epi= epicardium, AL= anterior leaflet, PL= 





Figure 2. 18 Activated β-catenin is prominent in proteoglycan enriched region. 
Representative images of E13.5 AV valves and E17.5 mitral valves 
immunostained for activated β-catenin (red), HABP (green) and nuclei 
counterstained with Hoechst (blue). PL=posterior leaflet, AL=anterior leaflet, 





        Human myxomatous mitral valves have increased nuclear β-catenin. 
        To determine the importance of canonical Wnt/β catenin signaling in 
human myxomatous valves, activated and membrane bound β-catenin 
antibodies were used to stain human valve tissues. Similar to what was 
observed in murine adult tissues (Figure 2.14), unaffected human valve tissue 
had undetectable β-catenin expression. However, the human myxomatous 
valve had increased expression of both activated and membrane bound β-























Figure 2. 19 Human myxomatous mitral valves have increased nuclear β-
catenin 
 
Representative images of human myxomatous and health control valve tissues 
immunostained for both forms of β-catenin (red) and nuclei counterstained 













        β-catenin is a member of the armadillo family proteins which plays a 
significant role in cadherin-based cell-cell adhesion and is an indispensable 
co-activator of Wnt-mediated gene expression[218, 234-236]. The dynamic 
regulation of its subcellular distribution, driven by phosphorylation and/or 
dephosphorylation events likely dictate its versatile functions[237].  
        Within the membrane, β-catenin is a critical component of the adherens 
junction which helps stabilize intercellular interactions[208]. This Ca2+ 
dependent cell-cell adhesion event is fundamental for regulating 
morphogenetic processes such as endocardial stabilization post-EMT[238, 
239]. The function of β-catenin at the membrane is distinct from its unique 
transcriptional-regulating properties within the nucleus[240]. Of note, we 
propose that care should be given in interpreting Lef1 data and/or reporter 
systems that use Lef1 as a readout for β-catenin nuclear activities. Our data 
demonstrate that co-expression of Lef1 with nuclear β-catenin is minimal 
within the heart. It remains possible that β-catenin is interacting with other 
TCF factors within the heart. Future studies should reveal whether these 
additional factors are co-expressed and interact with β-catenin and are needed 
to activate or repress target gene transcription. Regardless, our expression 




correlates with active growth and proliferation of the heart. As the heart 
matures, we observe a reduction in nuclear expression coincident with known 
timepoints of reduced proliferation[68]. Previous studies have revealed that 
loss of β-catenin or the β-catenin antagonist, Axin2, can result in profound 
valvulopathies in mice[57]. Based on our detailed subcellular expression 
maps for β-catenin, it seems most likely that the phenotypes have their origins 
in altered intercellular communications, and not due to altered nuclear 
presence of β-catenin. If true, this concept would be consistent with other 
findings in the mitral and aortic valve that have linked disease phenotypes to 
altered cell-cell interactions, including recent studies on the cadherin proteins 
DCHS1 and CAD-11 [241-243]. Thus, we posit that understanding how 
cadherin biology and intercellular interactions drive valve morphogenesis at 
the level of the membrane may reveal new mechanisms of development that 











Chapter 3 DZIP1 regulates mammalian cardiac valve development through a 






































        Mitral valve prolapse (MVP) affects 2-3% of the general population and 
is associated with secondary co-morbidities such as arrhythmias, heart failure 
and sudden cardiac death[166, 244-246]. MVP is characterized as the 
billowing of one or both leaflets above the level of the mitral annulus during 
cardiac systole. Structural changes of the valve result in an inability for the 
valve to be mechanically proficient during the cardiac cycle. These changes 
are characterized by alterations in the amount and types of extracellular matrix 
(ECM) present within the valves[247]. For example, increased proteoglycan 
and collagen deposition are evident with fragmented collagen and elastin 
being present. The loss of normal zonal boundaries is evident with expansion 
of proteoglycans throughout the valve layers. Valve interstitial cells (VICs) 
are thought to contribute to valve degeneration by becoming activated into 
myofibroblasts which undergo hyperplasia and produce excess ECM and 
growth factor ligands. Over time, the valve becomes thickened and floppy 
which results in incompetence, prolapse and mitral regurgitation. Surgery is 
the only curative option for patients with severe MVP[247-249]. 
        To date, the molecular and cellular causes of MVP are poorly 
understood[247]. Recent genetic studies have revealed a role for primary cilia 




disease initiation. Recently, mutations in the cilia gene DZIP1 were reported 
in multiple families with inherited, autosomal dominant non-syndromic 
MVP[128]. DZIP1 is a zinc finger protein localized to the basal body and 
nucleus and can regulate various downstream pathways involved in hedgehog 
and Wnt/β-catenin signaling[254-256]. However, how Dzip1 mutations result 
in MVP is unknown. 
        To investigate the mechanism of DZIP1 in MVP, we identified Chibby-
1 (CBY1) a binding partner of DZIP1 thorough proteomics analyses. CBY1 
is not only a ciliary gene essential for both motile and primary cilia 
assembly[257-261], but has also been shown to be a weak β-catenin 
antagonist by directly interacting with β-catenin to affect nuclear vs 
cytoplasmic shuttling of β-catenin[262-264]. In this chapter we report that a 
protein complex consisting of DZIP1-CBY1 and β-catenin are required for 
valve morphogenesis and disruption of their interactions cause valve defects 
and alterations in ECM production that progress to myxomatous degeneration. 
Additionally, identification of a multigenerational family with a rare, 
potentially damaging mutation within the DZIP1-CBY1 interaction domain 







        CBY1 Interacts and colocalizes with DZIP1 in developing mitral valves  
        To identify direct binding partners for DZIP1 in the heart, yeast two-
hybrid screens were performed where full length DZIP1 was used as the bait. 
We screened 113 million clones from a human embryonic and adult heart 
library. Table 1.1 highlights the prevalent DZIP1 interactors in the heart. 
PPP2R5A and vimentin had previously been identified as directly interacting 
with DZIP1, thus serving as positive controls for the experiment. CBY1, was 
the next highest prioritized interactor from our study and was further analyzed. 
Co-immunoprecipitations (Co-IPs) confirmed an interaction between DZIP1 
and CBY1 in HEK293T cells (Figure 3.1A). Co-expression of CBY1 and 
DZIP1 was analyzed by immunohistochemistry (IHC) at E13.5. As shown in 
Figure 3.1B and C, Dzip1 and Cby1 show overlap at the basal body of 
primary cilia in valve mesenchyme. Whereas Dzip1 is observed both at the 
basal body and in the nucleus as we previously reported[128], Cby1 appears 
enriched at the basal body. Within the basal body, the pattern of both Dzip1 
and Cby1 appear similar and stain only a small fraction of this subcellular 
structure, suggesting a function within a discrete portion of the basal body. 




representing unique subcellular expression domains or various snapshots of 





























Table 1.1 DZIP1 Interactors 
Yeast two-hybrid screening showing previously identified DZI1 interactors 
(yellow) and DZIP1-CBY1 interaction (green) with very high confidence 








Figure 3. 1 Cby1, Identified as Dzip1’s binding partner, localizes to primary 
cilia basal body in developing mitral valves 
A, Co-Immunoprecipitation (IP) and immunoblotting (IB) analysis of DZIP1 
with CBY1 in HEK293T whole-cell lysis. Co-IP was performed using FLAG 
or HA antibodies reciprocally. B, Representative images of E13.5 murine 
atrioventricular canal cushions (AVC) immunostained for Dzip1 (red), Cby1 
(green) and nuclei counterstained with hoechst (blue). Arrows, Dzip1/Cby1. 
C, Representative images of E13.5 murine AVC immunostained for Arl13b, 
γ-tubulin, Cby1, Dzip1 and nuclei counterstained with hoechst  
(blue). Left panel: Arl13b (green), Dzip1/Cby1 (red); Right panel: γ-tubulin 
(red), Dzip1/Cby1 (green). Bottom panel: 3D reconstruction of Cby1 (red) 







        Mapping of the DZIP1-CBY1 interaction domain 
        Various amino and carboxyl-termini deletion constructs for DZIP1 were 
generated and expressed in HEK293T cells followed by Co-IP in order to 
identify CBY1-interaction motifs. Constructs expressing just the N-terminal 
356 amino acids (1-356) failed to interact with CBY1. Likewise, constructs 
only expressing the amino acids 613-to the C-terminus (613-867) were unable 
to interact with CBY1. However, amino acids 357-612 revealed a positive 
interaction between DZIP1 and CBY1 (Figure 3.2A). This region was further 
dissected into two polypeptide stretches and tested by Co-IP. As shown in 
Figure 3.2B, only region 485-612 harbors the DZIP1-CBY1 interaction motif. 
Fine mapping of this region was performed by generating biotinylated 30-35 
amino acids overlapping peptides and tested by Co-IP (Figure 3.2C). Within 
this region we identified a bipartite interaction motif whereby 2 unique 
peptides (amino acids 531-560 and 564-593) were capable of interacting with 
CBY1 (P2: 531-560 and P5:564-593). Scrambled and reverse peptides for P5 
served as negative controls and failed to show an interaction as expected. 
Computational modeling of the peptides revealed similarities between these 2 
peptides in conformation indicating a potential likelihood of interacting with 
overlapping/similar residues on CBY1 (Figure 3.3A, B). Heatmap analyses 




regions of the CBY1 protein indicating that structurally, these two regions of 




























Figure 3. 2 Refined DZIP1-CBY1 interaction domain on DZIP1 
A, Co- IP and IB analysis of CBY1 with varies DZIP1 truncated constructs in 
HEK293T whole-cell lysis. B, Co-IP and IB analysis of CBY1 with DZIP1-
(357-484)/DZIP1-(485-612) in HEK293T whole-cell lysis. C, Co-IP and IB 
analysis of CBY1 with peptides in HEK293T whole-cell lysis. 
Scrambled (SC P5) and Reverse (Rev P5) peptides for P5 served as negative 












Figure 3. 3 3D structural predictions for peptides.  
A, B, Computational modeling of the two peptides: P2 (A) and P5 (B). 
Modeling was generated through RaptorX. C, Heatmap analysis of predicted 
peptide binding residues within CBY1 across P2 and P5. Red box, similar 







        DZIP1 peptide interacts with CBY1 and β-catenin.  
        As Cby1 was previously shown to directly interact with β-catenin[154], 
we used Co-IP experiments to test whether Dzip1 was capable of a β-catenin 
interaction through a CBY1 linker moiety. As shown in Figure 3.4A, full 
length (FL) Dzip1 was able to interact with both CBY1 and β-catenin. When 
we tested the amino end (1-356) DZIP1 expression construct, no interaction 
with CBY1 or β-catenin was observed, as expected. When the C-terminal 357-
867 amino acids of DZIP1 were tested, a CBY1 interaction was detected, but 
β-catenin was not evident in the IP reaction. This paradoxical observation 
indicated that upon CBY1 binding to DZIP1, the amino end of DZIP1 may be 
important in stabilizing the β-catenin interaction. It also remains possible that 
in the absence of the amino end of DZIP1, the 357-867 DZIP1 polypeptide 
folds around CBY1, encasing the protein, hindering interaction with other 
proteins. To test this hypothesis, we assayed whether the minimal DZIP1-
CBY1 interaction motif (peptide 5), was sufficient to pull down the entire 
complex. As shown in Figure 3.4B, peptide 5 (P5) was able to co-
immunoprecipitate both CBY1 and β-catenin in cultured human valve 
interstitial cells. Subsequent immunohistochemistry confirmed that β-catenin 




coincident with the temporal-spatial presence of both Dzip1 and Cby1 



















Figure 3. 4 DZIP1 interacts with β-catenin through CBY1 
A, Co-IP and IB analysis of β-catenin with DZIP1 in HEK293T whole-cell 
lysis. (1-356), amino acids 1-356 within DZIP1; (357-867), amino acids 357-
867 within DZIP1; FL, full length DZIP1. HEK293T cells were co-transfected 
with full length DZIP1-HA / (1-356) DZIP1-HA/ (357-867) DZIP1-HA and 
β catenin-FLAG constructs. Co-IP was performed by pulling down HA tag. 
(1-356) DZIP1-HA served as negative control. B, Co-IP and IB analysis of β-
catenin with P5 in cultured human valvular interstitial cells (hVICs) whole-
cell lysis. Biotinylated P5 was incubated with hVICs lysate at 4 ℃ overnight 




Figure 3. 5 β-catenin locates to primary cilia in developing murine mitral 
valves at E13.5 
A, Representative images of E13.5 murine AVC immunostained for β-catenin 
(red), Arl13b (green) and nuclei counterstained with hoechst (blue). C’&C’’, 
arrows, β-catenin. B, Representative images of E13.5 murine AVC 
immunostained for β-catenin (red), γ-tubulin (green) and nuclei 
counterstained with hoechst (blue). D’, arrows, valvular endothelial β-catenin. 





        Loss of Dzip1 causes increased nuclear β-catenin and Lef1 
        An interaction between DZIP1, CBY1 and β-catenin combined with our 
co-expression studies showing Cby1 is only present at the basal body, 
suggested that the DZIP1-CBY1 complex was functioning to sequester β-
catenin. To test this hypothesis, we analyzed if loss of Dzip1 in the mitral 
valves would release this inhibition. As shown in Figure 3.6A and B, when 
Dzip1 is conditionally removed from endocardium and endocardial derived 
mesenchyme (Dzip1f/f; NfatC1Cre (+)) that populate the entire mitral valve, a 
statistically significant increase in activated, nuclear β-catenin is observed 
(p=0.0002) compared to control littermates at P0. This finding correlates with 
a significant increase in the β-catenin co-factor, Lef1 (p<0.01), which is 
required for its transcriptional regulatory function. Previous reports have 
indicated that β-catenin activities may be dependent on the presence of 
primary cilia[143, 148]. As Dzip1 conditional knockout and mutant mitral 
valves were previously shown to have reduced cilia length[128], it remained 
possible that this increase in β-catenin is due to loss of cilia, independent of a 
Dzip-Cby1 interaction. Analyses of activated β-catenin in cilia deficient 
(NfatC1Cre (+); Ift88f/f) conditional knockout mitral valves failed to reveal a 




(Figure 3.7). These data indicate that the presence of cilia in the mitral valve 























Figure 3. 6 DZIP1 MVP mutation results in increased β-catenin signaling 
A, Top: P0 Dzip1f/f; Nfatc1Cre+ murine mitral valves immunostained for pβ-
cateninS552 (red) and nuclei counterstained with hoechst (blue) compared to littermate 
control; bottom: P0 murine mitral valves immunostained for Lef1 (red) and nuclei 
counterstained with Hoechst (blue) compared to littermate control. B: Left: 
quantification of pβ-cateninS552 + cell percentage; middle: quantification of anterior 
leaflet cell number; right: quantification of Lef1+ cell percentage. Data are 
means ± SD, unpaired two‐tailed Student's t‐test. (n=3/genotype, ***P=0.0002, 











         
Figure 3. 7 Regulation of β-catenin is primary cilia - independent 
Top panel: Representative images of NfatC1Cre+; Ift88f/f P0 murine mitral valves 
immunostained for pβ-cateninS552 (red), MF20 (green) and nuclei counterstained 
with hoechst (blue) comparing to littermate control. Bottom panel: 
quantification of NfatC1Cre+; Ift88f/f P0 murine anterior leaflet for pβ-cateninS552 
+ cell percentage and total cell number comparing to littermate control. Data are 










        DZIP1 MVP mutation results in increased β-catenin signaling 
        Our previous data demonstrated that the DZIP1S24R/+ mutation found in 
MVP patients and its corresponding mutation in mice (Dzip1S14R/+) resulted in 
decreased protein stability and likely loss of function[128]. Thus, we tested 
whether this loss of Dzip1 protein would result in a similar increase in nuclear 
β-catenin as observed in our conditional Dzip1 knockout mice (Figure 3.2.6). 
As shown in Figure 3.8, we observed a significant increase in activated 
nuclear β-catenin and its co-factor, Lef1 in the developing mitral valves. 
Subcellular fractionation of MEFs isolated from E13.5 Dzip1S14R/+ and 
wildtype littermates revealed a similar finding of increased nuclear β-catenin 
and reduced fraction of cytosolic β-catenin (Figure 3.8B). Total levels of β-
catenin do not change in the MEFs nor do the total number of cells change in 
the valves. Coincident with this observation, cycloheximide experiments in 
Dzip1S14R/+ MEFs and wildtype controls defined a significant reduction in 
Cby1 half-life when Dzip1S14R was expressed. Note, that expression of Dzip1 
is undetectable in our Dzip1S14R/+ MEFs even in the presence of a wildtype 
allele (Figure 3.9). This is similar to what we observed for the human 
mutation in immortalized patient lymphoblasts and indicates that the mutant 





  Figure 3. 8 DZIP1 MVP mutation results in increased β-catenin signaling 
A, Left panel: Representative images and quantification of pβ-cateninS552 
+(red) cells on Dzip1S14R/+ mitral valves at P0 comparing to wild-type; right 
panel: representative images and quantification of Lef1+ (red) cells on 
Dzip1S14R/+ mitral valves at P0 comparing to wild-type. Nuclei were 
counterstained with hoechst (blue). Data are means ± SD, unpaired two‐tailed 








     
 









Figure 3. 9 CBY1 stability is reduced in context of DZIP1S14R presence 
Western blots (left) and quantification (right) of cycloheximide experiment 
for CBY1 in E13.5 Dzip1S14R/+ MEFs compared to wild type. MEFs were 
treated with cycloheximide at 100ng/ml for 48 hours. Data are means ± SD, 






        Identification of a missense mutation affecting the CBY1 interaction 
domain in a family with autosomal dominant MVP 
        Through our whole exome sequencing project of sporadic individuals 
and families with non-syndromic MVP, we identified a multigenerational 
family with a rare variant in DZIP1, DZIP1C585W/+ (Figure 3.10). The mutation 
is rare with a minor allele frequency of 0.0078 and is predicted to be damaging 
by SIFT and Polyphen. This particular variant has a CADD (combined 
annotation dependent depletion) score of 22.5, which places it in the top 1% 
of deleterious single-base changes possible in the entire genome and within 
the 95% confidence interval of gene-specific CADD scores corresponding to 
high-confidence pathogenic mutations for DZIP1. The mutation segregates 
through two generations of the family and all affected individuals harbor the 
mutation. None of the confirmed non-MVP individuals have the mutation. 
Patient II.2 had indeterminant echocardiography and the status of her mitral 
valve was unable to be fully assessed. We tested mutation pathogenicity by 
performing cycloheximide experiments on transfected HEK293 cells and 
observed that the DZIP1C585W mutation resulted in a decrease in protein 
stability with a reduced half-life from 16.97 hours to 1.05 hours (Figure 
3.11A). To test whether the mutation also had an effect on CBY1 stability a 




Figure 3.11B, expression of DZIP1C585W results in a premature loss of CBY1 






















         
Figure 3. 10 Identification of a missense mutation in DZIP1 in a family with 
autosomal dominant MVP  
Multigenerational family with inherited, autosomal dominant, non-syndromic 
MVP. Sanger sequencing identified a single missense mutation of DZIP1, 
resulting in a cysteine-to-tryptophan change. Population frequency showing 
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Figure 3. 11 DZIP1C585W stability is reduced and CBY1 stability is reduced in 
the context of DZIP1C585W  
A, Western blots (left) and quantification (right) of cycloheximide experiment 
for DZIP1C505W compared to DZIP1 in HEK293T whole-cell lysis. Data are 
means ± SD, unpaired two‐tailed Student's t‐test. (n=3, **P<0.01). B, 
Western blots (left) and quantification (right) of cycloheximide experiment 
for CBY1 in presence of DZIP1C585W compared to presence of DZIP1 in 
HEK293T whole-cell lysis. Data      are means ± SD, unpaired two‐tailed 







        MVP DZIP1C585W mutation alters protein structure and binding to β-
catenin and CBY1  
        A peptide containing the C585W mutation was synthesized and is 
designated P5’ since its sequence is identical to that of the P5 peptide with the 
exception of the cysteine to tryptophan change. This peptide was tested for its 
ability to alter interactions with the CBY1-β-catenin complex. As shown in 
Figure 3.12A, both P5 and P5’ were capable of interacting with CBY1 and β-
catenin. However, in all repeated experiments (N=5), the P5’ mutant peptide 
demonstrated greater band intensity on the Co-IP reactions, suggesting an 
increased affinity for CBY1 and β-Catenin. This result was confirmed in 
transfected HEK293 cell lines as well as primary mitral valve interstitial cells 
during development. This result was strikingly similar to what we observed 
between P5 and the P2 segment, with the P2 peptide showing enhanced 
binding compared to P5 (Figure 3.2). Protein modeling and comparative 
structural predictions for each of the peptides was performed using RaptorX. 
Secondary and tertiary models for each of the peptides revealed a similar 
overall structure between P2 and P5’ (Figure 3.12B). Quantification of data 
obtained from structure modeling indicated that the cysteine to tryptophan 
(C585W) point mutation in the P5 subunit causes a drastic change in protein 




modification renders the P5 C585W mutant more structurally similar to the 
P2 WT subunit (Lali: 18; RMSD: 2.28; TM Score: 0.3925) compared to the 
P5 WT subunit (Lali: 7; RMSD: 1.90; TM Score: 0.1780). Therefore, although 
the mutation causes faster degradation of the full-length protein, it is 
structurally more similar to the P2 region and confers increased binding to the 


























Figure 3. 12 MVP DZIP1C585W mutation alters protein structure and binding 
to β-catenin and CBY1 
A, Co-IP and IB analysis of P5 and mutant P5 (C585W) with CBY1 in 
HEK293T whole-cell lysis and cultured hVICs whole-cell lysis. P5’, mutant 
P5 (C585W); Rev P5, reversed P5; SC P5, scrambled P5. Biotinylated 
peptides were incubated with cell lysis overnight at 4 ℃, and peptides were 
pulled down by streptavidin beads. B, 3D modeling of P5/P5’/P2 showing 
overall similarity between P2 and P5’. Venn diagram: quantification of 
modeling data indicating P5 C585W mutant is more structurally similar to the 





        β-catenin transcriptional responses are regulated through Dzip1 decoy 
peptides 
        To determine whether transducing cells with these minimal interaction 
motifs could affect downstream β-catenin activities, we synthesized various 
peptides based on our Co-IP data and human DZIP1 mutation. Peptides for 
the P5 region as well as mutant P5 (P5’) and a P5 reverse peptide were 
synthesized with a cell-penetrating TAT peptide sequence and a 5-FAM 
moiety for fluorescent visualization at the amino terminus. Peptides were also 
biotinylated to be able to confirm interaction with CBY1 and β-catenin. As 
shown in Figure 3.13, the 5-FAM-TAT labeled P5 was capable of interacting 
with both CBY1 and β-catenin in valve interstitial cells whereas the reverse 















Figure 3. 13 TAT conjugated P5 forms complex with CBY1 and β-catenin in 
cVICs 
Co-IP and IB analysis of β-catenin with TAT conjugated P5 in cVICs whole-
cell lysis. TAT conjugated P5 was incubated with cVICs lysate at 4℃ 
overnight and was pulled down by streptavidin beads. Reverse P5 served as 
negative control. Rev, reverse P5. TAT conjugated peptides on the gel were 











        To test whether the peptides function to disrupt β-catenin activities 
within the cell, valve interstitial cells were transfected with the TOP flash β-
catenin reporter plasmids. Forty-eight hours post-transfection, valve 
fibroblasts were stimulated with P5 (1μM, 10μM), P5’ (1μM) or reverse 
peptide (high dose 10μM). As shown in Figure 3.14A, membrane permeant 
peptides were able to traverse the cell membrane and enter the cytoplasm. Cell 
viability and substrate attachment were not grossly affected with peptide 
administration. Localization of the peptides can be seen perinuclear and along 
the cell membrane. Presence of the peptides within the nucleus are not evident, 
suggesting potential retention of β-catenin outside of the nucleus. Luciferase 
readouts from the TOPflash reporter confirmed a significant reduction in β-
catenin activities when treated with both the P5 and P5’ mutant peptides at 
1μM dose (Figure 3.14B). P5 treatment at 10μM dose resulted in a complete 
block in TOPflash luciferase activation whereas the reverse peptide had no 
significant effect at this higher dose. Interestingly, the mutant P5’ peptide was 
not as robust in repressing the reporter as the wild-type, even though it showed 



















Figure 3. 14 Dzip1 decoy peptides disrupts β-catenin transcriptional responses 
in vitro. 
A, Representative images of P5/P5’/P5 Rev treated chicken valvular 
interstitial cells (cVICs) for 24 hours at 10 μM. cVICs were transfected with 
TOP/FOPflash reporter construct for 48 hours before peptide treatment. P5’, 
C585W mutant P5; P5 Rev, reverse P5. B, Luciferase assay of P5/P5’/Rev P5 
treated cVICs. β-Gal was used as internal control. Data are means ± SD, 





        Enhanced MMP2 expression and altered extracellular matrix deposition 
in Dzip1S14R/+ and Cby1+/- postnatal mitral leaflets 
        Enhanced Wnt/β-catenin signaling has been observed in human 
myxomatous valves[60, 265, 266]. Hyperactivated β-catenin can promote 
endothelial-to-mesenchyme transformation (EMT), endocardial proliferation, 
ECM remodeling and myxomatous degeneration of mitral valves[56, 57, 267]. 
In this study as well as our previous reports on Dzip1 mutations, we observe 
similar findings of increased β-catenin activities within the valves during 
development in a model (Dzip1S14R/+) that was previously validated as having 
myxomatous valves and MVP[128]. For this study, we initially focused on 
MMP2 a known transcriptional target of β-catenin signaling that is also known 
to be upregulated in mitral valve disease. As shown in Figure 3.15, we 
observe increased MMP2 within the interstitium of Cby1 heterozygote 
(Cby1+/-) mitral valves by postnatal day 0. This finding of increased MMP2 
was also observed in the Dzip1S14R/+ model of MVP. Although our previous 
RNAseq data showed an increase in collagen I mRNA at this timepoint, IHC 
in both Cby1 and Dzip1 models show a loss of collagen protein within the 
valve. The reduction of collagen I, a known target of MMP2 enzyme activity 
was striking, especially along the atrialis of the mitral leaflets and is indicative 




myxomatous valves. Interestingly, periostin, a known β-catenin 
transcriptional target is also upregulated in the Cby1+/- valves, which is 
consistent with findings in human myxomatous valves and in hyperactive β-
























Figure 3. 15 Enhanced MMP2 expression and altered extracellular matrix 
deposition in Dzip1S14R/+ and Cby1+/- postnatal mitral leaflets 
A. Representative images of Cby1+/- P0 anterior leaflet immunostained for 
collagen I (red), MF20(green), periostin (red), MMP2 (green) and nuclei 
counterstained with hoechst (blue) comparing to wild type (N=3/genotype). 
B. Representative images of Dzip1S14R/+ P0 mitral valves immunostained for 
collagen I (red), MF20(green), MMP2 (green) and nuclei counterstained with 
hoechst (blue) comparing to wild type (N=3/genotype). Dotted line highlights 










        The genetic causes of mitral valve prolapse are only now beginning to be 
discovered. Once disease genes are identified, it will be important to identify 
the role that these genes play in disease initiation and progression. We recently 
identified mutations in the DZIP1 gene in multiple families with inherited non 
syndromic mitral valve prolapse. Through CRISPR-Cas9 genome editing, a 
murine model for non-syndromic MVP based on a human mutation was 
generated (Dzip1S14R/+). Utilizing a combination of proteomic based 
approaches with in vivo and in vitro studies, our findings reveal a mechanism 
by which myxomatous degeneration may occur through altered 
developmental pathways that invoke both ciliogenesis and β-catenin signaling. 
Previous studies have indicated that primary cilia can regulate canonical 
Wnt/β-catenin signaling[143, 148]. This is thought to occur through 
localization of Wnt receptors on the axoneme of the primary cilia and/or 
within the ciliary clefts. However, within cilia deficient mitral valves at P0, 
our studies did not reveal a significant change in activated nuclear β-catenin. 
Thus, our findings in our Dzip1 models of increased β-catenin/Lef1 signaling 





        Our recent studies have highlighted a dynamic expression pattern 
between nuclear and membrane bound β-catenin[265]. Whereas nuclear β-
catenin is present during early embryonic development, a shift to the 
membrane is observed during fetal gestation and is maintained after birth. 
This likely highlights the multifaceted role for this protein in both nuclear and 
membrane function. Mechanisms by which this nuclear vs cell membrane 
decision is made are not well understood, but likely critical for restricting β-
catenin’s transcriptional function. Our studies highlight the unique possibility 
that β-catenin is held at the basal body through a Dzip1-Cby1 complex. Co-
IP studies confirmed the formation of this complex and identified unique 
protein motifs that are critical for this interaction to occur. Generation of 
membrane permeant peptides of the Dzip1-Cby1 interaction motif were 
sufficient to potently suppress β-catenin transcriptional regulation in vitro. 
However, it is unlikely that the peptides would confer sufficient structure to 
restrict the entire peptide-Cby1-β-catenin complex to the basal body. It is 
more likely that the interaction of the Dzip1-decoy peptide facilitates 
stabilization of a Cby1-β-catenin complex and inhibits nuclear shuttling 
independent of being sequestered at the basal body. This is further supported 
by our anecdotal evidence showing that loss of Dzip1 and/or mutations within 




concomitant with increased nuclear β-catenin and upregulation of 
transcriptional activities.  
        Whole exome sequencing identified a multi-generational family with a 
rare, damaging variant in the DZIP1-CBY1 interaction motif. Peptide 
analyses and Co-IP studies revealed that this mutation altered the 3D structure 
of the protein and conferred a paradoxical increase in Cby1-β-catenin 
interactions. This should theoretically result in an increase in the stability of 
the complex and a reduction in β-catenin activity. However, this is 
confounded by our data showing that the Dzip1C585W mutation results in a 
profound reduction in protein half-life and premature degradation of CBY1 
protein. Thus, although the DZIP1C585W mutation appears to enhance an 
interaction with the complex, the reduced protein expression results in an 
overall loss of function, consistent with our other MVP-identified mutation, 
DZIP1S24R and our Dzip1 conditional knockout mice. 
        How altered β-catenin signaling may lead to a myxomatous valve and 
mitral valve prolapse is poorly understood. Previous reports have shown that 
either loss or gain of β-catenin function can result in a myxomatous 
phenotype[54, 56, 57]. In the context of Dzip1 and Cby1, our data show that 
loss of either of these genes impairs ciliogenesis (ref 12 and Figure 3.16). 




development results in transcriptional activation of numerous ECM genes 
including collagens and proteoglycans. In the context of increased collagens, 
one might expect to observe a fibrotic valve. Certainly, this occurs in the 
context of various other valve disease such as serotonin or drug-induced (e.g. 
fenfluramine, ergotamine) valvulopathies where the valves show stiff “stuck-
on plaques” and clear evidence of fibrosis. The phenotypes of these valves are 
very different from a floppy myxomatous valve, which is defined as having 
increased proteoglycans as well as fragmented collagen and elastin. This 
highlights that additional signaling pathways are likely in play to explain the 
fragmentation of collagen and the loss of properly stratified ECM boundaries. 
In this context, fragmentation of collagen would permit encroachment of 
proteoglycan proteins that can move via interstitial fluid flow within affected 
regions of the valve, particularly within the fibrosa. We believe our 
observation of increased MMP2 in our Dzip1 and Cby1 deficient mitral valves 
is significant since MMP2 is a direct target of β-catenin/Lef1 transcriptional 
regulation. Major substrates for this enzyme are collagens I, III, IV, V, VII, 
elastin and TGF-β. Transcripts for each of these ECM genes are increased in 
both of our Dzip1 and Ift88 cilia deficient mice. However, there is an 
important discrepancy to note. The Ift88 conditional knockout (NfatC1Cre (+); 




This study paired with our previous study paradoxically shows that while 
Dzip1S14R/+ and Dzip1 conditional knockout mice (NfatC1Cre (+); Dzip1f/f) have 
increased transcripts for collagen and elastin genes, overall valvular collagen 
I protein levels are lower. The most likely explanation for this finding is that 
in a mutated Dzip1 tissue, increased β-catenin activity leads to upregulation 
of MMPs and subsequent proteolysis of collagens and elastin. Our study 
highlights that Dzip1 mutations result in a shift in the balance of ECM 
synthesis and destruction through loss of cilia and/or increased β-catenin 
signaling. This altered ECM homeostasis eventually leads to the generation of 

































Figure 3. 16 CBY1 is necessary for ciliogenesis during valve development 
Top panel, representative images of Cby1+/- P0 anterior leaflet immunostained 
for Arl13B (red), γ-tubulin (green) and nuclei counterstained with hoechst 
(blue) comparing to littermate control. Middle panel, representative images of 
Cby1+/- P0 anterior leaflet immunostained for acetylated-tubulin (red), γ-
tubulin (red) and nuclei counterstained with hoechst (blue) comparing to 
littermate control. Bottom panel, quantification of primary cilia length and 
percentage of ciliated cells for Cby1+/- P0 anterior leaflet compared to 






















































4.1. β-catenin expression profile during valvulogenesis 
        In Chapter 2, we used antibody which targets endogenous level of β-
catenin only when phosphorylated at Ser552. This phospho-β-catenin (Ser552) 
specifically locates to nucleus. As a transcription co-activator, nuclear β-
catenin binds Tcf/Lef1 family member to activated downstream Wnt target 
genes. But we did not observe fully overlapping of Lef1 and phospho-β-
catenin (Ser552) from IHC. The activities between Lef1 and β-catenin seemed 
to be mutually exclusive. Even though studies have shown the Lef1 
independent β-catenin pathway and β-catenin independent Lef1 pathway, 
questions still remain unsolved that whether phospho-β-catenin (Ser552) 
interacts with other Tcf/Lef1 family members such as Tcf1/Tcf3/Tcf4. 
Additional immunostainings for those members could be done through 
development to determine their co-localization with phospho-β-catenin 
(Ser552). Except for Ser552, there are other different phospho sites on β-
catenin dictating its nuclear localization, including Ser191, Tyr393, Ser 605, 
Ser675. The other question remained unknown is whether these 
phosphorylated β-catenin are present on valve tissue during development and 
if so, what is their association with different Tcf/Lef1 family members. Future 
study could use Mass Spectrometry to map out the phosphorylation sites from 




technique on valve tissue could be used to determine the interactions between 
β-catenin and Tcf/Lef1 family members.  
        Immunofluorescence stainings in Chapter 2 are descriptive data. We 
know little about the mechanism behind the intriguing β-catenin expression 
patterns. In E13.5 AV valves, activated β-catenin are restricted within the 
central mass of the tissue and low to non-detectable staining is observed 
within subendothelial cells. This demarcates at least two different cell types. 
No studies have been done to characterize these two cell types despite they 
are all interstitial fibroblasts. The drastically different activated β-catenin 
expression patterns between the two subsets of cells indicate the different 
biological events these cells may go through. This information will be critical 
to shed a light on the VICs biogenesis and valvulogenesis. Future studies 
could use single-cell RNA-seq analysis to evaluated cell heterogeneity of 
VICs at E13.5. Flow cytometry could be used to sort cells using specific β-
catenin antibody.  
        Another question that is worthy for future study is why activated β-
catenin starts to present on endothelial cell membranes at E13.5 AV and aortic 
valves. The translocation from nuclei to cell membrane is highly associated 
with additional phosphorylation event mediated by other kinases. To test this, 




cell sorting (FACS). Mass Spectrometry could be used to identify new 
phospho sites. 
4.2. Regulation of Wnt/β-catenin signaling through Dzip1 
        In the 3rd Chapter, we identified a novel mechanism about how β-catenin 
is sequestered by Dzip1-Cby1 complex in cytoplasm. A segment of Dzip1 
protein (P5) is capable to substitute for Dzip1. The P5-Cby1 complex is able 
to sequester β-catenin in cytoplasm in vitro. The interesting phenomenon is 
that the mutant P5 (P5’) seems to have higher affinity to Cby1/β-catenin than 
wild type P5 according to stronger Cby1 signal detected from Co-IP. This 
leads to the postulation that mutant P5 should sequester more β-catenin in 
vitro and the luciferase reporter read out should be lower than wild type P5. 
But the fact is somehow on the contrary to our expectation that P5’ treated 
cells actually had a higher luciferase reporter read out than wild type P5. The 
cause is most likely due to the decreased stability of the P5’. Despite the 
higher affinity to β-catenin, P5’ gets degraded faster. The shortened P5’half-
life counteracts its inhibition on β-catenin, which leads to a higher β-catenin 
activity than wild type P5 in vitro. As mutant Dzip1 protein has a shortened 
half-life, the mutant peptide might have the same fate. In order to test the that, 
future study could use fluorescence-HPLC (High Performance Liquid 




        The identification of the P5 to inhibit β-catenin signaling is not only 
critical for valvular disease treatment, but important for cancer suppression. 
One of the human cancers caused by Wnt/β-catenin signaling hyperactivation 
is colorectal cancer (CRC). The other avenue of future direction is to test the 
effect of this peptide to inhibit hyperactivated Wnt/β-catenin signaling in CRC. 
We have detected the expression of both CBY1 and DZIP1 in Caco2 (human 
colorectal adenocarcinoma cells) cell lysates. Validation of CBY1-DZIP1-β-
catenin complex in Caco2 could be done through Co-IP.  Future studies could 
be done by incubating the Caco2 cells with P5 and control peptide and 
determine the localization of β-catenin by ICC. Western blot could be used to 
determine the nuclear β-catenin and cytoplasmic β-catenin expression. 
Anticipated results would be less nuclear β-catenin and more cytoplasmic β-
catenin with P5 than control peptide.  
        Another segment of DZIP1 that is able to interact with CBY1 is peptide 
2 (P2). A comparison between P2 and P5 could be studied in the future. We 
could compare the stability through fluorescence-HPLC. We could also 
compare the binding affinity to β-catenin and CBY1 through quantitative GST 
pull down. Through comparisons, we can select a more superior candidate to 
be potentially investigated clinically. The whole advantage of using the 




effects. The cell penetrating peptide (CPP) is a substitute for DZIP1 in the β-
catenin sequestration complex. It does not affect DZIP1’s other biological 
functions. Trough titration experiment, we could be able to find a proper 
dosage to offset the hyperactivated β-catenin signaling and keep the signaling 





























































        Wnt/β catenin signaling is one of the most important developmental 
signaling pathways that controls cell fate decisions and tissue patterning 
during early embryonic and later development. β-catenin is the key effector 
responsible for transduction of the signal to the nucleus and it triggers 
transcription of Wnt-specific gene responsible for the cell fate decision in 
many cells and tissue. Especially in heart valve development, β-catenin 
involves in the proliferation in AVC EMT and hyperactivated β-catenin leads 
to myxomatous ECM in mitral valve. 
        Even though several studies have revealed the critical roles of 
Wnt/signaling pathway in valvulogenesis, no information about the temporal 
and spatial distribution of activated β-catenin during valve development is 
known. Research work in Chapter 2 characterized the expression profile of 
activated β-catenin, which accounts for the Wnt signaling and membrane 
bound β-catenin, which mainly functions in maintaining cell-cell adhesion 
during valve development. We noticed a reduced nuclear β-catenin expression 
beginning at E13.5 and nuclear β-catenin started to relocate from nuclei to 
membrane as cardiac valves developed. This process is synchronizing cell 
proliferation which is also reduced with development as cardiac cells become 
more differentiated and mature[68]. Our study first reports the redistribution 




which is contrast to what we used to think about activated β-catenin. Once 
Wnt ligand bind Fz receptor on cell membrane, the deconstruction of β catenin 
phosphorylation complex which phosphorylates residues 41,37, and 33 of β 
catenin prevents β-catenin from degradation, thus, activated β-catenin is 
capable to accumulate in cytosol and has a chance to bind Tcf/Lef1 to recruit 
complexes that promote transcriptional activation[56]. The activated β-
catenin analyzed here in our study is phosphorylated at Ser552 by Akt which 
has been shown to have enhanced β-catenin/Tcf reporter activation[268-270]. 
However, many other residues in membrane cadherins could enhance the 
binding with β-catenin, as well. The local cell-signaling events, kinases and 
in vivo phosphorylation of cadherins, β-catenin and Tcf/Lef1 could make this 
redistribution significantly diverse during development. The data indicate that 
after E11.5, a subset of subendocardial cells start to go through a different 
biological process creating a biased affinity of β-catenin to membrane vs. 
nuclei.  
        Another important discovery is that within the developing mitral and 
aortic valves, nuclear β-catenin is profoundly downregulated. The activated 
nuclear β-catenin is not detectable in adult tissue. This gives rise to the 
question that since Wnt/β-catenin signaling is only activated during a 




phenotype is associated with dysregulated Wnt/β-catenin signaling? The 
activated nuclear β-catenin was most robust at E11.5 and start to be 
downregulated as early as E13.5. This time window is very critical for EMT. 
When this downregulation mechanism is not working and β catenin signaling 
is not constrained post-EMT, a variety of downstream target genes would be 
activated. This process can have lasting consequences throughout a lifetime. 
One of the most studied target gene is MMP2, which digest collagen and 
versican. The ECM components which are continuously digested by MMPs 
would not be proper to support valve tissue. The fragile valve might not be a 
problem early in life, but as heart develops and blood volume in cardiac 
circulation increases, the sheer force and continuous heartbeat would finally 
overwhelm the valve structure and leads to prolapse. 
        Above all, multiple functional β catenin present on cell membrane and 
nuclei is developmentally regulated. Their temporospatial expression pattern 
indicate their distinct roles in cell-cell adhesion, transcriptional activity, ECM 
deposition during different gestational timepoint. Later studies are needed to 
clarify the mechanisms involving those cellular events and take into 





        The research work in Chapter 3 starts with a genetic mutation in DZIP1 
that out lab previously identified within non-syndromic MVP families. 
Previous study of our lab has validated the correlation between DZIP1S14R and 
myxomatous phenotype. The mechanism of how DZIP1 regulates 
valvulogenesis remains unknow. Through proteomics approach, we identified 
and confirmed a molecular interaction between DZIP1 and CBY1 and their 
spatiotemporal co-localization on mitral valve tissues. CBY1 is a well-
established ciliary gene which functions in cilia formation[257-261]. On Cby1 
deficient valve tissues, we observed shortened and reduced number of primary 
cilia which supports those studies. Even though our study firstly validated the 
connection between DZIP1 and CBY1, some previous studies have actually 
indicated clues of this interaction by showing that both Cby1 and Dzip1 
interact with Fam92 to facilitate ciliogenesis[258, 271]. Along with our 
previous study on the ciliogenetic function of Dzip1[128], all these evidences 
strengthen the cooperative role of Dzip1 and Cby1 in ciliogenesis. 
        Jean-André Lapart et al. showed that Drosophila Dzip1 is required to 
recruit or stabilize Cby1 at centrioles, but does not depend on Cby1 for its 
targeting to centrioles[271]. This conclusion gives rise to a hint that the higher 
functional hierarchy of DZIP1maintains this collaboration between DZIP1 




corroborated that CBY1 became less stable in the context of either 
DZIP1C604W or DZIP1S14R meanwhile both DZIP1S14R and DZIP1C604W have 
impaired protein stability.  
        Cby1 is also a well-known β-catenin antagonist which is recognized to 
compete with Tcf/Lef1 to bind β-catenin and re-locate β-catenin outside 
nucleus into cytoplasm[154, 262, 263]. The molecular interaction between 
DZIP1 and CBY1 is reminiscent of the possibility that DZIP1 could interact 
with β-catenin through CBY1. This assumption was validated by the Co-IP 
experiment. Together with the significantly increased nuclear β-catenin from 
Dzip1 deficient mitral valve, these data strongly suggested that Dzip1 plays a 
vital role in restricting β-catenin signaling through Cby1. The decreased 
protein stability of CBY1 under conditions of DZIP1 mutant shed a light for 
the mechanism involved in how DZIP1 regulates β-catenin. 
        From the data collected we propose the following working model 
(Figure 4.1). In VICs, DZIP1, CBY1 and β-catenin form a complex which 
locates to basal body of a primary cilium. The complex sequesters β-catenin 
in cytoplasm. This leads to the shut off of the β-catenin signaling. The ECM 
homeostasis is balanced as there would be no extra MMPs induction. When 
DZP1 has a mutation, its protein stability is impaired which leads to the 




disrupted. β-catenin will be set free and enter nucleus to start downstream 
MMPs transcription. This contributes to ECM digestion. Over time, the valve 
tissue become thickened and mechanically incompetent. 
        In the future this work has the potential to influence therapies for 
myxomatous valvular diseases. The peptides used in this work showed 
striking effect on β-catenin signaling inhibition. Therapies using Nano 
particles which filled with the peptides are appealing for this function. Using 
antibody targeted against VICs, these peptides could possibly turn off the 
hyperactivated β-catenin signaling in VICs before they produce too much 
MMPs to digest collagens.  
        Many questions remain to be answered and more work is needed to 
further elucidate the molecular mechanisms involved in valve disease, 
however, considerable progress has been made towards increasing our 
knowledge about it. The identification of a complex formed by DZIP1-CBY1-
β-catenin to regulate Wnt signaling during valvulogenesis is innovative and 
opens up the potential for further research to refine our knowledge about the 
genetic and molecular landscape of valve development.   













Figure 4. 1 Graphic Abstract 
DZIP1, CBY1 and β-catenin form a complex which locates to basal body. 
This complex sequesters β-catenin in cytoplasm and β-catenin signaling is 
being withheld. When Dzip1 has a mutation, its protein stability is impaired 
and is not able to stabilize DZIP1-CBY1-β-catenin complex. β-catenin will 
be set free and enter nucleus to start downstream MMPs transcription which 











































        Mouse husbandry and genotyping.  
        Dzip1 conditional mice and Dzip1 knock in mice were genotyped and 
generated as previously described[128, 272]. Cby1 mice were a kind gift from 
Dr. Ken-Ichi Takemaru. C57Bl6 mice were purchased from Charles river. 
Animals were kept in a 12-hour light-dark cycle with food and water ad 
libitum. Genotyping was performed by Transnetyx, Inc or inhouse with the 
KAPA Mouse Genotyping Kit (Kapabiosystems, #KK7301). 
        Immunohistochemistry (IHC) and fluorescence imaging. 
Immunohistochemical and fluorescence stains were performed on 5 μm, 
paraffin-embedded sections from embryonic timepoints (E11.5, E13.5), fetal 
gestation (E17.5), neonatal (P0), and adult (6-month). Human mitral valve 
samples were processed and sectioned as previously described[181]. Sections 
were subjected to antigen unmasking (H‐3300; Vector Laboratories, 
Burlingame, CA) and treated for 1 hour at room temperature with a blocking 
buffer of PBS (Sigma, St. Louis, MO) containing 1% BSA (Sigma, B4287-
25G). Primary antibodies used were: mouse gamma tubulin (sigma, 
T6557,dilution 1:100) rabbit acetylated tubulin (cell signaling, 5335S,dilution 
1:100), rabbit Arl13B(Protein tech, 17711-1-AP, dilution 1:500), activated β-
catenin (Cell signaling, #9566S, 1:100), total β-catenin (cell signaling, 




PCAM-1 (Dianova, #DIA-310, 1:50), hyaluronan binding protein (HABP) 
(Calbiochem #385911, 1:100) and LEF1 (cell signaling, #2230S, 1:100). To 
determine the activated β-catenin distribution during valvulogenesis, we 
stained for β-cateninpS552. Both Akt and PKA were shown to phosphorylate β-
catenin at Ser552[268, 273]. Phosphorylation at Ser552 induces β-catenin 
accumulation in the nucleus and increases its transcriptional activity [268-
270]. Specificity of these antibodies were validated as recognizing the 
appropriate epitopes in various model systems, including knockout animals 
and cell lines[181, 270, 274-277]. Primary antibodies were placed in blocking 
buffer overnight at 4°C. Following primary antibody incubations, specimens 
were washed five times in PBS and incubated at room temperature with Alexa 
Fluor goat α‐rabbit 568 and goat α‐mouse 488 (Invitrogen, Eugene, OR) 
diluted 1:100 in PBS. Nuclei were stained with Hoechst dye (1:10,000; 
Invitrogen) in PBS for 5 min prior to the final washes in PBS. All samples 
were cover‐slipped using Dabco mounting medium (Sigma). Images of 
immunostained sections were captured with Zeiss Axioimager M2 and Leica 
TCS SP5 AOBS Confocal Microscope System (Leica Microsystems, Inc., 410 
Eagleview Boulevard, Suite 107, Exton, PA 19341). Z-stacks were set by 




system optimized setting to determine steps. Z-stacks were then compiled to 
form maximum projection images[129].N>3/timepoint or genotypes. 
        Yeast 2 Hybrid Screen 
        Y2H screens were performed by Hybrigenics Services (Paris, France; 
www.hybrigenics-services.com). The coding sequence of the full-length 
Homo sapiens DZIP1 (isoform 2) was PCR-amplified and cloned in frame 
with the LexA DNA binding domain (DBD) into plasmid pB27 as a C-
terminal fusion to Gal4 (Gal4-bait fusion). The DZIP1-DBD bait protein was 
used to screen a human embryonic and adult cardiac library. A total of 274 
prey fragments of the positive clones were amplified by PCR and sequenced 
at their 5’ and 3’ junctions.  
        Interaction confidence scoring 
        Predicted Biological Score (PBS) was attributed to each interaction as 
previously described[278]. The PBS score represents the probability of an 
interaction being non-specific which is primarily based on the comparison 
between the number of independent prey fragments found for an interaction 
and the chance of finding them at random (background noise). The value in 
the scores A to D varies between 0 and 1 (A < 1e-10 < B < 1e-5 < C < 1e-2.5 
< D < 1). Several thresholds were arbitrarily defined in order to rank the 




A: Very high confidence in the interaction. 
B: High confidence in the interaction. 
C: Good confidence in the interaction. 
D: Moderate confidence in the interaction.  
E: Interactions involving highly connected (or relatively highly connected) 
prey domains, warning of non-specific interaction.  
F: Experimentally proven technical artifacts. 
        Generation of Dzip1 expression constructs and TAT-fusion peptides 
        Control human DZIP1-Myc-DDK plasmid was purchased from Origene 
(clone ID: 198968). Truncated DZIP1 plasmids were sub-cloned with a HA 
tag sequence at the C terminus using pTARGETTM Mammalian Expression 
Vector System (Promega, Cat No: A1410). The Dzip1 mutation was 
incorporated through a QuickChange II XL Site-Directed Mutagenesis Kit 
(Agilent Technologies) based on the manufacturer’s recommendations and 
had a HA-epitope tag at the C terminus. CBY1 plasmid with a HA-epitope tag 
at C terminus was purchased from Sino Biological (clone ID: BC016139). 
CBY1 plasmid with a Flag-epitope flag at the C terminus was a kind gift from 
Dr.Ken-Ichi Takemaru and described previously[258].All clones were 
sequenced through Genewiz before use. TAT-fusion peptides were 




        Cell culture 
        Human valvular cells were isolated and cultured in DMEM with 15% 
fetal calf serum and antibiotics (P/S, fungizone) as described previously[181]. 
Chicken valvular interstitial cells (cVICs) were isolated from anterior leaflet 
of chicken embryos at HH40 as described before[279]. cVICs were 
maintained in Medium 199 (M199, Invitrogen) containing 5% of chicken 
serum (bioworld),0.1% ITS (gibco,41400-045) and 1% antibiotics (P/S, 
fungizone). Dzip1S14R/+ or wild type mouse embryonic fibroblast(MEFs) were 
derived according to the protocol published before[280] and were cultured in 
DMEM with 10% FBS and antibiotics (P/S, fungizone). For all experiments, 
these valvular interstitial cells were utilized prior to passage 5. Hek293T cells 
were maintained in DMEM with 10% fetal bovine serum and antibiotics (P/S, 
fungizone).  
        Primary cilia measurement 
        For measuring the cilia length in the Cby1 control (Cby1+/+) versus 
Cby1+/-, values were plotted every 0.5 μm to assess cilia length distribution 
differences between the two genotypes at P0. We chose 3 slides from each 
animal, and imaged three pictures at different parts on anterior leaflets (tip, 
middle, root). 3 or 4/genotype were included. Cilia length measurements were 




alpha tubulin/arl13b, gamma tubulin and counterstained with Hoechst. Z-
stack images were then imported into Imaris software and measurements were 
taken from the base to the tip of the axoneme. All cilia in the field of view 
were measured. For control mitral leaflets, a total of n=1266 cilia lengths 
quantified. For Cby1+/-mitral leaflets a total of n=497 cilia lengths 
quantified[128]. Cell numbers from each image were counted blindly by two 
people. n=26 images were counted from wild type and n=25 images were 
counted from Cby1+/-. 
        Co-IP and Western blotting 
        Hek 293T cells were seeded at 5X105 /well on 6-well plates one day 
before transfection. Cells were co-transfected with DZIP1 and CBY1 
plasmids using FuGENE HD transfection Reagent (Promega, Cat No: E2311) 
for 72 hours and were lysed using ice-cold lysis buffer (25mM Tris HCL, 
150mM Nacl, 1% NP-40,5% glycerol) with Halt protease and phosphatase 
Inhibitor cocktail(100x) being added before (Thermo Scientific, Cat 
NO:78440, dilution 1:500) followed by incubating on ice for 30 minutes with 
intermittent vortex. Preclearing of the cell lysates were done by adding 2.5 ul 
of IgG with the same species as primary antibody and 25ul of Pierce Protein 
A/G Agarose beads (Thermo Scientific, Cat NO:20421) into cell lysates 




antibody or IgG together with 50ul of Pierce Protein A/G Agarose beads were 
incubated with cell lysates at 4 ℃ overnight. Beads were collected and washed 
with 1ml of ice-cold lysis buffer for 5 times before SDS-PAGE. For peptide 
Co-IP, HEK293T or human valvular interstitial cell lysates were incubated 
with Pierce Streptavidin Magnetic Beads (Pierce, Cat NO:88816) and 
biotinylated peptide at 4 ℃ overnight. Collect and wash magnetic beads 
according manufacture’s manual before SDS-PAGE. The primary antibodies 
used for Co-IP assays and Western blotting were as follows: mouse Flag M2 
(Sigma,dilution 1:1,000), rabbit HA (Sigma,Cat NO:SAB4300603, dilution 
1:1,000).rabbit CBY1(Protein tech, Cat NO: 12239-1-AP, dilution 1:1,000), 
rabbit β catenin(cell signaling, Cat NO: 9581, dilution 1:1,000). Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were purchased from 
Sigma (dilution 1:10,000). 
        Computational Studies: 
        RaptorX Structure Alignment was used to align the protein structures of 
interest: P5 wild type (WT), P5 C585W mutant, P2 WT[281, 282]. RaptorX 
employs a statistical learning method to calculate the compatibility between a 
target sequence and a template structure [283]. Protein structures were 
prepared using PEP-FOLD 3: a publicly available software capable of de novo 




Protein structures were exported as PDB files and submitted for analysis by 
the RaptorX Structure Alignment Server. RaptorX calculates the structural 
similarity of two or more proteins by comparing the length of the core (Lali), 
root mean squared deviation (RMSD), and template modeling score (TM 
score). For multiple structure alignment (MSA), Lali is the length of core, 
which consists of all the fully aligned columns [281, 282]. The RMSD is 
calculated only on the core residues. The TM score is the measure of similarity 
between two or more protein structures with different tertiary structures. The 
TM Score ranges from 0-1.0: If TM score >0.6, there is a 90% chance that 
two proteins share a similar fold. When TM score <0.4, there is a 90% chance 
that two proteins have different folds. 
        Peptide treatment and reporter assay in cVICs 
        cVICs were seeded at 5X105 /well on 6-well plates. The next day, cells 
were transfected with 1.6μg TopFlash (Addgene plasmid # 12456) or 
FopFlash (Addgene plasmid # 12457) and 0.4 μg b-galactosidase-encoding 
construct. Transfections were performed using FuGENE HD transfection 
Reagent (Promega, Cat No: E2311) and cells were incubated at 37℃ for 24 
hours. TAT-fusion peptide was added at 10 μM or 1 μM 24 hours post 




and firefly luciferase activities were evaluated using the Luciferase Assay 
System (Promega, E1500). 
        Protein stability analysis 
        HEK293T cells were seeded at 5x105 /well on 6-well plate. On the next 
day, cells were co-transfected with wild type DZIP1-Flag or DZIP1C604W-Flag 
and CBY1-HA constructs using FuGENE HD transfection Reagent (Promega, 
Cat No: E2311). Cycloheximide were added 48 hours post transfection at 
concentration of 100ng/ml. Cells were lysed with RIPA buffer at 0/4/8/16/32 
hours after cycloheximide treatment. Dzip1S14/+ and wild type MEFs were 
seeded at 2X105/well on 6-well plate and treated with cycloheximide at 
concentration of 100ng/ml the next day. Cell lysates were harvested using 
RIPA buffer at 0- and 48-hours post cycloheximide treatment. 
Immunoblotting was performed as described previously[181]. Primary 
antibody used for western blotting were as follows: mouse Flag M2 (Sigma), 
rabbit HA (Sigma, Cat NO: SAB4300603), rabbit CBY1(Protein tech, Cat NO: 
12239-1-AP), rabbit DZIP1 (Protein tech, Cat NO: 13779-1-AP), mouse actin 
(Millipore, Cat No: MAB1501). HRP-conjugated secondary antibodies were 
purchased from Sigma. 




        Dzip1S14R/+ and wild type MEFs from E13.5 embryos were plated at 
2x105 /well on 6-well plate. On the next day, cells were digested with trypsin 
and washed with 1x PBS twice and fragmentation was done following the 
instruction of NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo, Cat NO:78835). Nuclear and cytoplasmic extractions were collected 
for Western Blotting. β-Catenin was normalized by total protein indicated by 
Ponceau S. 
        Human studies 
        All studies involving human research were approved by the Institutional 
Review Board Institut du Thorax, Nantes, France and all participants provided 
written informed consent. 
        Familial genetics and WES 
        Exome sequencing was performed on the proband (II.4). Exome capture 
was carried out using the SureSelect Human All Exon System using the 
manufacturer’s protocol version 1.0 (Agilent Inc.) that is compatible with 
Illumina paired-end sequencing. Exome-enriched genomes were multiplexed 
by flow cell for 101-bp paired-end read sequencing according to the protocol 
for the HiSeq 2000 sequencer (version 1.7.0; Illumina) to allow a minimum 
coverage of 30Å~. Reads were aligned to the human reference genome 




Quality control to determine sample and genotyping quality and to potentially 
remove poor SNPs and/or samples was performed as we have previously 
published[181]. Follow up Sanger sequencing was performed on the rest of 
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